Comprehensive Cardiovascular Pharmacotherapy: Chronic Disease, Acute Coronary Syndromes, and Critical Cardiac Care

Heart Failure: Chronic Management and Acute Decompensation

Heart failure is a complex clinical syndrome resulting from any structural or functional cardiac disorder that impairs ventricular filling or the ejection of blood. In the United States, heart failure affects approximately 6.2×1066.2\times 10^6 individuals, and its prevalence rises substantially with advancing age. Heart failure with reduced ejection fraction (HFrEF\text{HFrEF}) is clinically defined by symptoms of heart failure and a left ventricular ejection fraction (LVEF\text{LVEF}) of 40%40\% or less, characterized pathologically by ventricular dilation and adverse remodeling. Approximately two-thirds of HFrEF\text{HFrEF} cases are secondary to chronic coronary disease (CCD\text{CCD}) following myocardial infarction, while one-third stem from nonischemic cardiomyopathies including chronic uncontrolled hypertension, thyroid disorders, severe obesity, stress cardiomyopathy (Takotsubo), viral or autoimmune myocarditis, tachycardia-mediated cardiomyopathy, peripartum cardiomyopathy, cardiotoxic exposures such as alcohol and cocaine, and chemotherapeutic agents including anthracyclines, high-dose cyclophosphamide, fluorouracil, trastuzumab (with or without pertuzumab/hyaluronidase), and mitoxantrone.

Heart failure with preserved ejection fraction (HFpEF\text{HFpEF}) is defined by an LVEF\text{LVEF} of 50%50\% or greater, representing approximately 50%50\% of all heart failure presentations. The fundamental pathophysiology in HFpEF\text{HFpEF} involves impaired ventricular relaxation and decreased compliance leading to elevated diastolic filling pressures despite normal wall motion and preserved pump function. Hypertension is the principal etiologic contributor, documented in 60%60\% to 89%89\% of affected patients. Additional clinical classifications include heart failure with mildly reduced ejection fraction (HFmrEF\text{HFmrEF}), defined as an LVEF\text{LVEF} of 41%41\% to 49%49\% alongside evidence of increased left ventricular filling pressures, and heart failure with improved ejection fraction (HFimpEF\text{HFimpEF}), defined as a baseline LVEF\text{LVEF} of 40%40\% or less that exhibits a subsequent follow-up measurement of greater than 40%40\% with an absolute improvement of at least 10%10\%.

The American College of Cardiology/American Heart Association (ACC/AHA\text{ACC/AHA}) staging system categorizes heart failure across four developmental phases, which correspond to the New York Heart Association (NYHA\text{NYHA}) functional classification based on subjective symptomatic limitation. Stage A represents patients at high risk for heart failure due to uncontrolled predisposing conditions (such as hypertension, metabolic syndrome, or diabetes) but without structural heart disease, abnormal stretch/injury cardiac biomarkers, or symptoms (no NYHA\text{NYHA} class). Stage B (Pre-heart failure) comprises patients with structural heart disease (such as left ventricular hypertrophy or chamber enlargement), elevated filling pressures, or elevated brain natriuretic peptide (BNP\text{BNP}) or persistently elevated cardiac troponin in the absence of signs or symptoms (NYHA\text{NYHA} Class I: asymptomatic without limitation in physical activity). Stage C (Symptomatic heart failure) denotes patients with structural cardiac abnormalities and past or current clinical symptoms (NYHA\text{NYHA} Class I through IV). Class II reflects slight physical limitation where normal exertion precipitates dyspnea or fatigue, Class III reflects marked limitation where less-than-ordinary exertion produces symptoms but the patient remains comfortable at rest, and Class IV denotes an inability to carry out any physical activity without discomfort or the presence of symptoms at rest. Stage D represents advanced heart failure with refractory symptoms interfering with daily life and recurrent hospitalizations despite maximal guideline-directed medical therapy (GDMT\text{GDMT}).


Heart failure treatment algorithms across clinical phenotypes

Guideline-directed medical therapy for chronic HFrEF\text{HFrEF} prioritizes four foundational drug classes to reduce cardiovascular mortality and heart failure hospitalizations: an angiotensin receptor-neprilysin inhibitor (ARNI\text{ARNI}), an evidence-based β\beta-blocker, a mineralocorticoid receptor antagonist (MRA\text{MRA}), and a sodium-glucose cotransporter 2 (SGLT2\text{SGLT2}) inhibitor. Initiation does not require sequential completion of individual drug titrations; rather, simultaneous or rapid sequential initiation guided by renal function, serum potassium, heart rate, and blood pressure is recommended, with dose titrations occurring as frequently as every 11 to 2 weeks2\,\text{weeks}.

Angiotensin receptor-neprilysin inhibitors, specifically sacubitril/valsartan, carry a Class I recommendation over angiotensin-converting enzyme (ACE\text{ACE}) inhibitors or angiotensin receptor blockers (ARBs\text{ARBs}) for patients with chronic symptomatic HFrEF\text{HFrEF} (NYHA\text{NYHA} Class II to III) based on the PARADIGM-HF trial, which demonstrated a 20%20\% relative risk reduction in the primary composite endpoint of cardiovascular death or heart failure hospitalization, a 16%16\% reduction in all-cause mortality, and a 21%21\% reduction in heart failure hospitalizations compared with enalapril. Sacubitril is a prodrug that inhibits neprilysin, thereby preventing the degradation of natriuretic peptides, bradykinin, and adrenomedullin, while valsartan selectively blocks the angiotensin II type 1 (AT1\text{AT}_1) receptor. Because neprilysin degrades BNP\text{BNP}, circulating BNP\text{BNP} concentrations increase during ARNI\text{ARNI} therapy, whereas N-terminal pro-B-type natriuretic peptide (NT-proBNP\text{NT-proBNP}) is not a neprilysin substrate and reflects true hemodynamic unloading. When transitioning from an ACE\text{ACE} inhibitor to sacubitril/valsartan, a strict 36 hour36\,\text{hour} washout period is mandatory to minimize the risk of severe angioedema caused by overlapping inhibition of bradykinin degradation. For patients previously taking low-dose ACE\text{ACE} inhibitors (e.g., enalapril ≤10 mg/day\le 10\,\text{mg/day}, lisinopril ≤10 mg/day\le 10\,\text{mg/day}, ramipril ≤5 mg/day\le 5\,\text{mg/day}) or low-dose ARBs\text{ARBs} (valsartan ≤160 mg/day\le 160\,\text{mg/day}, losartan ≤50 mg/day\le 50\,\text{mg/day}), or those with an estimated glomerular filtration rate (eGFR\text{eGFR}) of less than 30 mL/min/1.73 m230\,\text{mL/min/1.73}\,\text{m}^2, the starting dose is sacubitril 24 mg24\,\text{mg} / valsartan 26 mg26\,\text{mg} orally twice daily. For patients switching from standard or high doses of an ACE\text{ACE} inhibitor or ARB\text{ARB}, the initial dose is sacubitril 49 mg49\,\text{mg} / valsartan 51 mg51\,\text{mg} twice daily. Doses should be doubled every 22 to 4 weeks4\,\text{weeks} toward the target maintenance dose of sacubitril 97 mg97\,\text{mg} / valsartan 103 mg103\,\text{mg} orally twice daily.

When an ARNI\text{ARNI} is not feasible due to cost, intolerance, or history of angioedema, ACE\text{ACE} inhibitors represent a Class I alternative, supported by landmark trials including CONSENSUS, SOLVD, SAVE, AIRE, and TRACE, which documented a 25%25\% to 50%50\% relative risk reduction in mortality and a 30%30\% reduction in hospitalizations. The ATLAS trial established that higher target doses of lisinopril (32.532.5 to 35 mg/day35\,\text{mg/day} vs. 2.52.5 to 5 mg/day5\,\text{mg/day}) resulted in a significant 12%12\% lower risk of death or hospitalization and 24%24\% fewer hospitalizations for heart failure, underscoring the clinical imperative to titrate to target doses: captopril 50 mg50\,\text{mg} three times daily (starting at 6.25 mg6.25\,\text{mg} three times daily), enalapril 10 mg10\,\text{mg} twice daily (starting at 2.5 mg2.5\,\text{mg} twice daily), lisinopril 20 mg20\,\text{mg} daily (starting at 2.52.5 to 5 mg5\,\text{mg} daily), perindopril 8 mg8\,\text{mg} daily (starting at 2 mg2\,\text{mg} daily), ramipril 10 mg10\,\text{mg} daily (starting at 1.251.25 to 2.5 mg2.5\,\text{mg} daily), and trandolapril 4 mg4\,\text{mg} daily (starting at 1 mg1\,\text{mg} daily). In patients intolerant of ACE\text{ACE} inhibitors due to intractable cough (20%20\% incidence) or angioedema (<1%< 1\% incidence; cross-reactivity with ARBs\text{ARBs} is approximately 2.5%2.5\%), ARBs\text{ARBs} are indicated (Class I): candesartan titrated from 44 to 8 mg8\,\text{mg} daily to a target of 32 mg32\,\text{mg} daily (CHARM-Alternative), losartan titrated from 2525 to 50 mg50\,\text{mg} daily to a target of 150 mg150\,\text{mg} daily (HEAAL), or valsartan titrated from 2020 to 40 mg40\,\text{mg} twice daily to a target of 160 mg160\,\text{mg} twice daily (Val-HeFT, VALIANT). Renal function and potassium must be evaluated within 11 to 2 weeks2\,\text{weeks} of initiation or dose escalation; an increase in serum creatinine of up to 30%30\% above baseline is considered an acceptable hemodynamically mediated decline in glomerular filtration rate resulting from efferent arteriolar vasodilation.

Evidence-based β\beta-blockers (bisoprolol, carvedilol, and metoprolol succinate) carry a Class I recommendation and confer an approximate 35%35\% relative reduction in mortality and a 25%25\% reduction in hospitalizations (CIBIS II, COPERNICUS, MERIT-HF). Non-evidence-based agents (e.g., atenolol, metoprolol tartrate) lack demonstrated survival benefit, as demonstrated in the COMET trial where carvedilol proved superior to metoprolol tartrate. Carvedilol offers combined nonselective β\beta- and α1\alpha_1-adrenergic blockade, inducing peripheral vasodilation and greater systemic blood pressure reduction than metoprolol succinate. Initiation requires hemodynamic stability and absence of overt fluid retention. Starting doses are bisoprolol 1.25 mg1.25\,\text{mg} daily (target 10 mg10\,\text{mg} daily), carvedilol 3.125 mg3.125\,\text{mg} twice daily (target 25 mg25\,\text{mg} twice daily, or 50 mg50\,\text{mg} twice daily for weight >85 kg> 85\,\text{kg}; controlled-release carvedilol 10 mg10\,\text{mg} daily titrated to 80 mg80\,\text{mg} daily), and metoprolol succinate 12.512.5 to 25 mg25\,\text{mg} daily (target 200 mg200\,\text{mg} daily). Doses should be doubled every 11 to 2 weeks2\,\text{weeks}. Fluid retention occurring during titration is managed by adjusting concomitant loop diuretics without discontinuing the β\beta-blocker unless frank cardiogenic shock ensues.

Mineralocorticoid receptor antagonists (spironolactone and eplerenone) carry a Class I recommendation for patients with NYHA\text{NYHA} Class II to IV symptoms to reduce morbidity and mortality (RALES, EMPHASIS-HF, EPHESUS). Spironolactone reduced all-cause mortality by 30%30\% and heart failure hospitalizations by 35%35\% in advanced heart failure, while eplerenone reduced cardiovascular death or heart failure hospitalization by 37%37\% in mild symptoms and mortality by 15%15\% post-myocardial infarction with systolic dysfunction. Initiation requires an eGFR>30 mL/min/1.73 m2\text{eGFR} > 30\,\text{mL/min/1.73}\,\text{m}^2 and a baseline serum potassium of less than 5.0 mEq/L5.0\,\text{mEq/L}. For an eGFR≥50 mL/min/1.73 m2\text{eGFR} \ge 50\,\text{mL/min/1.73}\,\text{m}^2, spironolactone is initiated at 12.512.5 to 25 mg25\,\text{mg} daily (maintenance 25 mg25\,\text{mg} daily or twice daily) and eplerenone at 25 mg25\,\text{mg} daily (maintenance 50 mg50\,\text{mg} daily). For an eGFR\text{eGFR} of 3030 to 49 mL/min/1.73 m249\,\text{mL/min/1.73}\,\text{m}^2, spironolactone is initiated at 12.5 mg12.5\,\text{mg} daily or every other day (maintenance 12.512.5 to 25 mg25\,\text{mg} daily) and eplerenone at 25 mg25\,\text{mg} every other day (maintenance 25 mg25\,\text{mg} daily). Serum potassium and creatinine must be assessed at 1 week1\,\text{week}, 1 month1\,\text{month}, and 6 months6\,\text{months} post-initiation; doses must be reduced by 50%50\% or suspended if potassium exceeds 5.5 mEq/L5.5\,\text{mEq/L}. Gynecomastia occurs in approximately 10%10\% of patients receiving spironolactone due to nonselective binding to androgen and progesterone receptors; eplerenone provides a selective alternative devoid of endocrine adverse effects.

Sodium-glucose cotransporter 2 inhibitors (dapagliflozin 10 mg10\,\text{mg} once daily and empagliflozin 10 mg10\,\text{mg} once daily) represent foundational therapy (Class I) for symptomatic HFrEF\text{HFrEF} irrespective of diabetes status. The DAPA-HF and EMPEROR-Reduced trials confirmed marked reductions in cardiovascular death and heart failure hospitalizations. Dapagliflozin is initiated at an eGFR≥25 mL/min/1.73 m2\text{eGFR} \ge 25\,\text{mL/min/1.73}\,\text{m}^2, and empagliflozin is indicated at an eGFR≥20 mL/min/1.73 m2\text{eGFR} \ge 20\,\text{mL/min/1.73}\,\text{m}^2. Mechanisms include osmotic diuresis, natriuresis, reductions in preload and afterload, decreased intraglomerular pressure, enhanced myocardial energetics, and attenuation of cardiac fibrosis. Adverse event monitoring focuses on mycotic genital infections, volume contraction, orthostatic hypotension, and rare euglycemic diabetic ketoacidosis (DKA\text{DKA}), necessitating temporary drug cessation 33 to 5 days5\,\text{days} prior to elective surgical procedures.

Loop diuretics inhibit 20%20\% to 25%25\% of sodium reabsorption in the thick ascending limb of the loop of Henle and are administered to achieve and maintain euvolemia (Class I). Oral bioavailability varies widely: furosemide displays erratic absorption (10%10\% to 67%67\%, average 50%50\%), bumetanide exhibits 80%80\% to 100%100\% absorption, torsemide exhibits 80%80\% to 100%100\% absorption, and ethacrynic acid exhibits 100%100\% absorption. Bioequivalent oral doses are furosemide 40 mg40\,\text{mg}, bumetanide 1 mg1\,\text{mg}, torsemide 1010 to 20 mg20\,\text{mg}, and ethacrynic acid 50 mg50\,\text{mg}. Oral-to-intravenous conversion is 2:12:1 for furosemide (40 mg40\,\text{mg} oral equals 20 mg20\,\text{mg} intravenous) and 1:11:1 for bumetanide, torsemide, and ethacrynic acid. Ethacrynic acid represents the primary non-sulfa option for patients with true severe sulfonamide allergies. Daily dosing should aim for a weight reduction of 0.50.5 to 1.0 kg/day1.0\,\text{kg/day} during active fluid congestion. Serum electrolytes must be closely tracked to maintain potassium at 4.0 mEq/L4.0\,\text{mEq/L} or greater and magnesium at 2.0 mEq/L2.0\,\text{mEq/L} or greater to protect against life-threatening ventricular arrhythmias.

Hydralazine and isosorbide dinitrate combination therapy carries a Class I recommendation to reduce morbidity and mortality in self-described African American patients with NYHA\text{NYHA} Class III to IV HFrEF\text{HFrEF} receiving optimal background therapy (A-HeFT; 43%43\% relative reduction in mortality) and a Class IIa recommendation in patients unable to tolerate an ARNI\text{ARNI}, ACE\text{ACE} inhibitor, or ARB\text{ARB} due to severe renal impairment or hyperkalemia. Dosing utilizes a fixed combination (BiDil: hydralazine 37.5 mg37.5\,\text{mg} / isosorbide dinitrate 20 mg20\,\text{mg}) initiated at 1 tablet three times daily and titrated to a target of 2 tablets three times daily, or separate generic components titrated up to hydralazine 300 mg/day300\,\text{mg/day} and isosorbide dinitrate 120 mg/day120\,\text{mg/day} in divided doses. Hydralazine mediates arterial vasodilation (afterload reduction) and blunts nitrate tolerance through antioxidant mechanisms, while isosorbide dinitrate provides venous capacitance dilation (preload reduction). Adverse effects include headache, reflex tachycardia, hypotension, and dose-related drug-induced lupus erythematosus.

Ivabradine selectively inhibits the hyperpolarization-activated cyclic nucleotide-gated (IfI_f) inward funny current in the sinoatrial node, slowing the diastolic depolarization slope and lowering heart rate without affecting ventricular repolarization or contractility. It carries a Class IIa recommendation to reduce heart failure hospitalizations in patients with stable, symptomatic HFrEF\text{HFrEF} (LVEF≤35%\text{LVEF} \le 35\%), in sinus rhythm with a resting heart rate of 70 beats/min70\,\text{beats/min} or greater, who are receiving maximally tolerated doses of guideline-directed β\beta-blockers (SHIFT trial; 18%18\% reduction in cardiovascular death or heart failure hospitalization). Starting doses are 5 mg5\,\text{mg} twice daily with meals (or 2.5 mg2.5\,\text{mg} twice daily for age ≥75 years\ge 75\,\text{years}), titrated after 22 to 4 weeks4\,\text{weeks} to a maximum of 7.5 mg7.5\,\text{mg} twice daily for resting heart rate >60 beats/min> 60\,\text{beats/min}, maintained if heart rate is 5050 to 60 beats/min60\,\text{beats/min}, or reduced/discontinued if heart rate falls below 50 beats/min50\,\text{beats/min}. Notable adverse effects include visual luminous phenomena (phosphenes; 3%3\%) and bradycardia or secondary atrial fibrillation (5%5\% to 8%8\%). Ivabradine is contraindicated in acute decompensated heart failure, baseline blood pressure below 90/50 mm Hg90/50\,\text{mm Hg}, pre-initiation resting heart rate below 60 beats/min60\,\text{beats/min}, sinoatrial block, severe hepatic impairment (Child-Pugh Class C), and concurrent use of strong CYP3A4 inhibitors.

Digoxin exerts positive inotropy by reversibly inhibiting myocardial sodium-potassium adenosine triphosphatase (Na+/K+-ATPase\text{Na}^+/\text{K}^+\text{-ATPase}) and modulates autonomic activity by sensitizing cardiac arterial baroreceptors to reduce central sympathetic outflow. In the DIG trial, digoxin produced a neutral effect on all-cause mortality but achieved a 28%28\% relative risk reduction in heart failure hospitalizations (Class IIb). Digoxin should be initiated without a loading dose in chronic heart failure at an oral maintenance dose of 0.125 mg/day0.125\,\text{mg/day} (or 0.125 mg0.125\,\text{mg} every other day in patients older than 70 years70\,\text{years}, those with renal dysfunction, or low lean body mass). Target serum trough concentrations are strictly maintained at 0.50.5 to 0.9 ng/mL0.9\,\text{ng/mL}. Concentrations of 1.0 ng/mL1.0\,\text{ng/mL} or greater are linked to increased mortality, especially among women and older adults. Manifestations of digitalis toxicity (anorexia, nausea, vomiting, yellow-green visual chromatopsia, scotomas, heart block, and ventricular arrhythmias) are exacerbated by hypokalemia, hypomagnesemia, and hypercalcemia. Digoxin concentrations are elevated by concurrent administration of amiodarone (reduce digoxin dose by 30%30\% to 50%50\%), dronedarone (reduce digoxin by 50%50\%), verapamil, clarithromycin, erythromycin, itraconazole, posaconazole, cyclosporine, and tacrolimus.

Vericiguat is an oral soluble guanylate cyclase (sGC\text{sGC}) stimulator that directly enhances cyclic guanosine monophosphate (cGMP\text{cGMP}) production independently of endogenous nitric oxide (NO\text{NO}) and sensitizes sGC\text{sGC} to residual endogenous NO\text{NO}, leading to smooth muscle relaxation and attenuation of myocardial and vascular remodeling. In the VICTORIA trial, vericiguat reduced the composite of cardiovascular death or heart failure hospitalization in high-risk patients with worsening HFrEF\text{HFrEF} (LVEF<45%\text{LVEF} < 45\%) who experienced a recent heart failure hospitalization or required intravenous diuretics (Class IIb). Dosing begins at 2.5 mg2.5\,\text{mg} once daily with food and is titrated every 2 weeks2\,\text{weeks} through 5 mg5\,\text{mg} to a target of 10 mg10\,\text{mg} once daily, provided systolic blood pressure remains at or above 100 mm Hg100\,\text{mm Hg}. Vericiguat is teratogenic, contraindicated in pregnancy, and cannot be combined with phosphodiesterase type 5 (PDE-5\text{PDE-5}) inhibitors or long-acting nitrates due to severe synergistic hypotension.

Additional supportive therapies include polyunsaturated fatty acids (PUFAs\text{PUFAs}), with prescription icosapent ethyl (2 g2\,\text{g} orally twice daily) or combined EPA/DHA\text{EPA/DHA} formulations (1000 mg1000\,\text{mg} daily containing 850 mg850\,\text{mg} of eicosapentaenoic acid and 882 mg882\,\text{mg} of docosahexaenoic acid) reasonable as adjunctive therapy to reduce cardiovascular death and hospitalizations (GISSI-HF, REDUCE-IT; Class IIb). Potassium-binding polymers, specifically patiromer (calcium-potassium exchanger; dose separated by 3 hours3\,\text{hours} from other oral medications; risk of hypomagnesemia) and sodium zirconium cyclosilicate (sodium/hydrogen-potassium exchanger; dose separated by 2 hours2\,\text{hours} from other oral medications; risk of sodium retention and edema), carry a Class IIb recommendation to manage recurrent hyperkalemia (K+≥5.5 mEq/L\text{K}^+ \ge 5.5\,\text{mEq/L}) and facilitate guideline-directed RAAS\text{RAAS} inhibitor and MRA\text{MRA} optimization (PEARL-HF, HARMONIZE). Primary prevention implantable cardioverter-defibrillators (ICDs\text{ICDs}) are indicated (Class I) in patients with ischemic or nonischemic cardiomyopathy, an LVEF≤35%\text{LVEF} \le 35\%, and NYHA\text{NYHA} Class II to III symptoms on chronic optimal medical therapy with a life expectancy greater than 1 year1\,\text{year}, at least 40 days40\,\text{days} post-myocardial infarction, or post-infarct patients with an LVEF≤30%\text{LVEF} \le 30\% and NYHA\text{NYHA} Class I symptoms. Cardiac resynchronization therapy (CRT\text{CRT}) is indicated for patients in sinus rhythm with an LVEF≤35%\text{LVEF} \le 35\%, left bundle branch block with a QRS\text{QRS} duration of 150 ms150\,\text{ms} or greater, and NYHA\text{NYHA} Class II to IV ambulatory symptoms on optimal therapy.

In HFpEF\text{HFpEF}, treatment targets blood pressure control (<130/80 mm Hg< 130/80\,\text{mm Hg}; Class I) and the management of fluid volume using diuretics (Class I). SGLT2 inhibitors carry a Class IIa recommendation based on clinical trials showing significant decreases in heart failure hospitalizations and cardiovascular mortality. MRAs\text{MRAs}, ARNIs\text{ARNIs}, and ARBs\text{ARBs} carry Class IIb recommendations to reduce hospitalizations, with benefits concentrated among patients with an LVEF\text{LVEF} at the lower end of the preserved spectrum (50%50\% to 57%57\%; TOPCAT, PARAGON-HF, CHARM-Preserved). β\beta-Blockers are not recommended for HFpEF\text{HFpEF} in the absence of competing indications (such as prior myocardial infarction or rate control of atrial fibrillation) due to observational signals of increased heart failure hospitalizations. In HFmrEF\text{HFmrEF}, SGLT2 inhibitors hold a Class IIa recommendation for reducing mortality and hospitalizations, while ARNIs\text{ARNIs}, ACE\text{ACE} inhibitors, ARBs\text{ARBs}, evidence-based β\beta-blockers, and MRAs\text{MRAs} carry Class IIb recommendations. In HFimpEF\text{HFimpEF}, foundational HFrEF\text{HFrEF} pharmacotherapy must be continued indefinitely; the TRED-HF randomized withdrawal trial demonstrated that discontinuing neurohormonal therapies precipitates rapid relapse of left ventricular dysfunction and heart failure recurrence.

Cardiotoxic and destabilizing medications that must be avoided or used with caution in heart failure patients include: nonsteroidal anti-inflammatory drugs (NSAIDs\text{NSAIDs}) and selective COX-2\text{COX-2} inhibitors, which promote sodium and water retention, induce afferent renal vasoconstriction, blunt diuretic responsiveness, and increase mortality; corticosteroids; minoxidil; thiazolidinediones (pioglitazone, rosiglitazone), which stimulate renal sodium reabsorption via peroxisome proliferator-activated receptor-gamma; Class Ia and Ic antiarrhythmics and dronedarone (which doubled mortality in decompensated heart failure); non-dihydropyridine calcium channel blockers (diltiazem, verapamil), which exert negative inotropic effects; itraconazole; dipeptidyl peptidase-4 (DPP-4\text{DPP-4}) inhibitors saxagliptin and alogliptin, which increase heart failure hospitalizations; central nervous system stimulants and amphetamines; pregabalin (which induces peripheral edema); and cilostazol, a phosphodiesterase type 3 inhibitor that increases ventricular arrhythmias and mortality in HFrEF\text{HFrEF}.

Acute decompensated heart failure (ADHF\text{ADHF}) manifests when compensatory mechanisms fail to preserve cardiac output and maintain normal filling pressures, often triggered by dietary nonadherence, medication omission, uncontrolled hypertension, acute myocardial ischemia, worsening mitral regurgitation, systemic infection, pulmonary embolism, alcohol or substance use, or development of tachyarrhythmias such as atrial fibrillation. Diagnostic evaluation relies on clinical assessment and serum natriuretic peptides. Heart failure is highly unlikely when BNP\text{BNP} is less than 100 pg/mL100\,\text{pg/mL} or NT-proBNP\text{NT-proBNP} is less than 300 pg/mL300\,\text{pg/mL}. Confirmatory NT-proBNP\text{NT-proBNP} cutpoints that establish heart failure diagnosis during acute dyspnea are age-stratified: 450 pg/mL450\,\text{pg/mL} for age younger than 50 years50\,\text{years}, 900 pg/mL900\,\text{pg/mL} for age 5050 to 75 years75\,\text{years}, and 1800 pg/mL1800\,\text{pg/mL} for age older than 75 years75\,\text{years}.

Hemodynamic profiling classifies patients into four clinical subsets according to volume status ("dry" vs. "wet") and systemic tissue perfusion ("warm" vs. "cold"). Congestion ("wet") reflects an elevated pulmonary capillary wedge pressure (PCWP>18 mm Hg\text{PCWP} > 18\,\text{mm Hg}), manifesting clinically as orthopnea, paroxysmal nocturnal dyspnea, jugular venous distension, hepatojugular reflux, pulmonary crackles, ascites, and peripheral edema. Hypoperfusion ("cold") reflects a depressed cardiac index (CI<2.2 L/min/m2\text{CI} < 2.2\,\text{L/min/m}^2), presenting with cool extremities, narrowed pulse pressure, declining renal function, altered mentation, and fatigue. Subset I ("Warm and Dry"; normal filling pressures, adequate perfusion: PCWP\text{PCWP} 1515 to 18 mm Hg18\,\text{mm Hg}, CI>2.2 L/min/m2\text{CI} > 2.2\,\text{L/min/m}^2) represents compensated disease requiring outpatient oral GDMT\text{GDMT} optimization. Subset II ("Warm and Wet"; congestion with preserved perfusion) is the most common presentation, managed with intravenous loop diuretics alongside intravenous vasodilators (nitroglycerin, nitroprusside) in the absence of symptomatic hypotension (SBP≥90 mm Hg\text{SBP} \ge 90\,\text{mm Hg}). Subset III ("Cold and Dry"; hypoperfusion without congestion: PCWP<15 mm Hg\text{PCWP} < 15\,\text{mm Hg}, CI<2.2 L/min/m2\text{CI} < 2.2\,\text{L/min/m}^2) requires cautious volume expansion with intravenous crystalloids to achieve an optimal filling pressure (PCWP\text{PCWP} 1515 to 18 mm Hg18\,\text{mm Hg}); if hypoperfusion persists once adequate preload is restored, inotropic support is initiated for an SBP<90 mm Hg\text{SBP} < 90\,\text{mm Hg}, or an arterial vasodilator is selected for an SBP≥90 mm Hg\text{SBP} \ge 90\,\text{mm Hg}. Subset IV ("Cold and Wet"; combined congestion and hypoperfusion) represents cardiogenic decompensation, requiring aggressive intravenous loop diuresis paired with inotropes (dobutamine or milrinone) if SBP<90 mm Hg\text{SBP} < 90\,\text{mm Hg}, or intravenous arterial/venous vasodilators if SBP≥90 mm Hg\text{SBP} \ge 90\,\text{mm Hg}.

In ADHF\text{ADHF}, pre-existing GDMT\text{GDMT} should be continued unless hemodynamic instability, cardiogenic shock, symptomatic bradycardia, or severe hyperkalemia supervenes. Withholding β\beta-blockers is associated with increased in-hospital and post-discharge mortality (OPTIMIZE-HF), though dose reduction or temporary suspension is necessary in cardiogenic shock or profound low-output states. Intravenous loop diuretic therapy should equal or exceed 1.01.0 to 2.5 times2.5\,\text{times} the home oral dose administered as intravenous boluses or continuous infusion (e.g., outpatient furosemide 80 mg80\,\text{mg} twice daily converts to 8080 to 200 mg200\,\text{mg} intravenous furosemide twice daily). Diuretic resistance is addressed by escalating the loop diuretic dose toward ceiling thresholds (160160 to 200 mg200\,\text{mg} of intravenous furosemide), transitioning to a continuous infusion (55 to 20 mg/hr20\,\text{mg/hr}, preceded by a loading bolus), or adding sequential nephron blockade with oral metolazone (2.52.5 to 5 mg5\,\text{mg} given 30 minutes30\,\text{minutes} prior to the loop diuretic), intravenous chlorothiazide (250250 to 500 mg500\,\text{mg} daily), or intravenous acetazolamide (500 mg500\,\text{mg} daily targeting proximal tubule bicarbonate and sodium reabsorption).

Intravenous vasodilators provide rapid symptomatic relief in acute pulmonary congestion. Intravenous nitroglycerin acts primarily as a venous capacitance dilator at lower doses (55 to 100\,\text{\mu g/min}) to lower PCWP\text{PCWP}, inducing modest arterial vasodilation only at higher infusion rates (up to 200\,\text{\mu g/min}); tachyphylaxis commonly develops within 2424 to 48 hours48\,\text{hours}. Sodium nitroprusside (0.10.1 to 0.2\,\text{\mu g/kg/min}, titrated up to 10\,\text{\mu g/kg/min}) is a balanced arterial and venous vasodilator that decreases systemic vascular resistance (SVR\text{SVR}) and ventricular filling pressures, demanding invasive arterial blood pressure monitoring to prevent profound hypotension; nitroprusside carries a risk of cyanide and thiocyanate toxicity, especially when infused for longer than 48 hours48\,\text{hours} or in patients with hepatic or renal impairment, and is avoided in myocardial infarction due to the risk of coronary steal. Intravenous inotropes (dobutamine, a β1\beta_1- and β2\beta_2-agonist dosed at 2.52.5 to 20\,\text{\mu g/kg/min}; and milrinone, a phosphodiesterase type 3 inhibitor that prevents cAMP\text{cAMP} breakdown, dosed at 0.1250.125 to 0.75\,\text{\mu g/kg/min}) increase intracellular calcium and enhance contractility, but both increase ventricular arrhythmias and mortality. Milrinone relies on renal clearance (90%90\%) and has an elimination half-life of 1 hour1\,\text{hour} that extends to 22 to 3 hours3\,\text{hours} in heart failure or renal dysfunction (and over 20 hours20\,\text{hours} in anuria), but remains effective during concomitant β\beta-blocker therapy due to its downstream mechanism. Dobutamine is favored in severe hypotension, severe renal dysfunction, or bradycardia, but loses efficacy in patients on chronic β\beta-blocker therapy. Oral tolvaptan (15 mg15\,\text{mg} daily, titrated to 3030 to 60 mg60\,\text{mg}) is an oral selective vasopressin V2V_2 receptor antagonist indicated for hypervolemic or euvolemic hyponatremia (Na+<125 mEq/L\text{Na}^+ < 125\,\text{mEq/L}, or symptomatic hyponatremia refractory to fluid restriction); it must be initiated in the inpatient setting, carries a maximum rate of sodium correction of 88 to 10 mEq/L10\,\text{mEq/L} per 24 hours24\,\text{hours} to avoid osmotic demyelination syndrome, and cannot be administered for longer than 30 days30\,\text{days} due to potential hepatotoxicity.

Acute Coronary Syndromes and Invasive Revascularization

Acute coronary syndrome (ACS\text{ACS}) encompasses a clinical continuum spanning unstable angina (UA\text{UA}), non-ST-segment elevation myocardial infarction (NSTEMI\text{NSTEMI}), and ST-segment elevation myocardial infarction (STEMI\text{STEMI}). Pathophysiologically, the primary event in type 1 myocardial infarction involves atheromatous plaque disruption (rupture or erosion) that exposes subendothelial collagen and von Willebrand factor to flowing blood, triggering platelet adhesion, activation, and aggregation, followed by coagulation cascade activation and thrombus generation. Complete coronary thrombotic occlusion produces transmural ischemia manifested as STEMI\text{STEMI}, whereas partial occlusion, microembolization, or transient total occlusion produces non-ST-segment elevation acute coronary syndrome (NSTE-ACS\text{NSTE-ACS}).

Clinical presentation typically includes retrosternal chest discomfort described as crushing, squeezing, pressure, or tightness radiating to the left arm, neck, jaw, or epigastrium, frequently accompanied by diaphoresis, dyspnea, nausea, and lightheadedness. A significant proportion of myocardial infarctions, particularly in female, diabetic, and elderly patients, present without chest pain, manifesting as "angina equivalents" such as unexplained exertional dyspnea, profound fatigue, indigestion, or syncope. Diagnostic evaluation mandates acquisition and expert interpretation of a 12-lead electrocardiogram (ECG\text{ECG}) within 10 minutes10\,\text{minutes} of first medical contact. Diagnostic criteria for STEMI\text{STEMI} require new ST-segment elevation measured at the J-point in two or more contiguous leads of at least 1 mm1\,\text{mm} (0.1 mV0.1\,\text{mV}), except in precordial leads V2V_2 and V3V_3, where sex- and age-specific thresholds apply. In NSTE-ACS\text{NSTE-ACS}, the ECG\text{ECG} may demonstrate ST-segment depression (≥0.5 mm\ge 0.5\,\text{mm}), T-wave inversions (≥1 mm\ge 1\,\text{mm}), or nonspecific ST-T abnormalities, or may appear normal. Serial high-sensitivity cardiac troponin (hs-cTnI\text{hs-cTnI} or hs-cTnT\text{hs-cTnT}) should be obtained at baseline and 11 to 3 hours3\,\text{hours} later, or conventional troponins every 33 to 6 hours6\,\text{hours}. Myocardial necrosis is confirmed when cardiac troponin concentrations exceed the 99th percentile upper reference limit (URL\text{URL}) accompanied by a rising or falling kinetic pattern; elevated troponins differentiate NSTEMI\text{NSTEMI} from UA\text{UA}.


Acute coronary syndrome diagnostic workflow and early risk stratification

Risk stratification in NSTE-ACS\text{NSTE-ACS} guides the selection of an early invasive strategy versus an ischemia-guided (conservative) approach using validated clinical risk engines. The Thrombolysis in Myocardial Infarction (TIMI\text{TIMI}) risk score compiles seven independent baseline variables (1 point each): age 65 years65\,\text{years} or older, three or more coronary artery disease risk factors, documented prior coronary stenosis of 50%50\% or greater, ST-segment deviation on presentation, two or more anginal episodes in the preceding 24 hours24\,\text{hours}, aspirin use within the prior 7 days7\,\text{days}, and elevated serum cardiac biomarkers. A TIMI\text{TIMI} score of 00 to 22 designates low risk, 33 to 44 intermediate risk, and 55 to 77 high risk of composite death, recurrent myocardial infarction, or severe ischemia within 14 days14\,\text{days}. The Global Registry of Acute Coronary Events (GRACE\text{GRACE}) risk calculator estimates in-hospital and post-discharge mortality based on age, heart rate, systolic blood pressure, serum creatinine, Killip class, cardiac arrest at presentation, ST-segment deviation, and cardiac biomarkers, where a GRACE\text{GRACE} score greater than 140140 designates high risk favoring an early invasive strategy within 24 hours24\,\text{hours}. High-risk angiographic features contributing to procedural complexity include multivessel disease, left main or proximal left anterior descending artery involvement, chronic total occlusions, complex bifurcations, severe calcification, extreme tortuosity, and lesions exceeding 20 mm20\,\text{mm} in length.

In STEMI\text{STEMI}, primary percutaneous coronary intervention (PCI\text{PCI}) is the reperfusion treatment of choice, provided it can be executed within a first medical contact-to-device door-to-balloon time of 90 minutes90\,\text{minutes} or less at a PCI-capable center, or within 120 minutes120\,\text{minutes} when interhospital transfer is required. Primary PCI\text{PCI} or emergent coronary artery bypass grafting (CABG\text{CABG}) is indicated in STEMI\text{STEMI} complicated by cardiogenic shock irrespective of time delay from symptom onset. When transfer for primary PCI\text{PCI} cannot achieve balloon inflation within 120 minutes120\,\text{minutes}, fibrinolytic therapy must be administered within a door-to-needle time of 30 minutes30\,\text{minutes} or less, provided symptom onset occurred within the preceding 12 hours12\,\text{hours} and absolute contraindications are absent. Absolute contraindications to fibrinolytics include any prior intracranial hemorrhage, known structural cerebral vascular malformation (such as arteriovenous malformation), known malignant intracranial neoplasm, ischemic stroke within the preceding 3 months3\,\text{months} (excluding acute ischemic stroke within 4.5 hours4.5\,\text{hours}), suspected aortic dissection, active internal bleeding or bleeding diathesis (excluding menses), significant closed-head or facial trauma within 3 months3\,\text{months}, intracranial or intraspinal surgery within 2 months2\,\text{months}, and severe uncontrolled hypertension refractory to acute emergency medical management. Relative contraindications comprise poorly controlled chronic hypertension, presentation blood pressure exceeding 180/110 mm Hg180/110\,\text{mm Hg}, history of ischemic stroke older than 3 months3\,\text{months}, prolonged or traumatic cardiopulmonary resuscitation (>10 minutes> 10\,\text{minutes}), major surgery within 3 weeks3\,\text{weeks}, recent internal hemorrhage (22 to 4 weeks4\,\text{weeks}), noncompressible vascular punctures, active peptic ulcer disease, current oral anticoagulant therapy, and pregnancy.

Fibrinolytic dosing regimens utilize fibrin-specific plasminogen activators: tenecteplase (TNK-t-PA\text{TNK-t-PA}) is administered as a single weight-tiered intravenous bolus over 5 seconds5\,\text{seconds} (<60 kg:30 mg< 60\,\text{kg}: 30\,\text{mg}; 6060 to 69 kg:35 mg69\,\text{kg}: 35\,\text{mg}; 7070 to 79 kg:40 mg79\,\text{kg}: 40\,\text{mg}; 8080 to 89 kg:45 mg89\,\text{kg}: 45\,\text{mg}; ≥90 kg:50 mg\ge 90\,\text{kg}: 50\,\text{mg}, equivalent to approximately 0.5 mg/kg0.5\,\text{mg/kg}); alteplase (t-PA\text{t-PA}) is administered as an accelerated, weight-adjusted infusion over 90 minutes90\,\text{minutes} (15 mg15\,\text{mg} intravenous push, followed by 0.75 mg/kg0.75\,\text{mg/kg} up to 50 mg50\,\text{mg} over 30 minutes30\,\text{minutes}, then 0.5 mg/kg0.5\,\text{mg/kg} up to 35 mg35\,\text{mg} over 60 minutes60\,\text{minutes}, maximum total dose 100 mg100\,\text{mg} for body weight >67 kg> 67\,\text{kg}); and reteplase (r-PA\text{r-PA}) is administered as a double bolus of 10 units10\,\text{units} intravenously followed by a second 10 unit10\,\text{unit} bolus 30 minutes30\,\text{minutes} later. Patients treated with fibrinolytics require concomitant full-dose parenteral anticoagulation for a minimum of 48 hours48\,\text{hours} and up to 8 days8\,\text{days} or until revascularization, using unfractionated heparin, weight-adjusted enoxaparin, or fondaparinux.

Initial acute anti-ischemic and analgesic therapy includes non-enteric-coated aspirin (162162 to 325 mg325\,\text{mg} chewed and swallowed immediately; Class I), which irreversibly acetylates platelet cyclooxygenase-1 (COX-1\text{COX-1}) to suppress thromboxane A2A_2 generation. Sublingual nitroglycerin (0.30.3 to 0.4 mg0.4\,\text{mg} every 5 minutes5\,\text{minutes} for up to three doses) is administered for ischemic chest pain, followed by continuous intravenous nitroglycerin (5\,\text{\mu g/min}, titrated up to 200\,\text{\mu g/min}) for ongoing ischemia, heart failure, or uncontrolled hypertension. Nitrates are strictly contraindicated within 24 hours24\,\text{hours} of sildenafil or vardenafil, within 48 hours48\,\text{hours} of tadalafil, in systolic blood pressure below 90 mm Hg90\,\text{mm Hg} or exceeding 30 mm Hg30\,\text{mm Hg} below baseline, severe bradycardia (<50 beats/min< 50\,\text{beats/min}), marked tachycardia (>100 beats/min> 100\,\text{beats/min} in the absence of heart failure), or suspected right ventricular infarction. Supplemental oxygen is indicated only if arterial oxygen saturation (SaO2\text{SaO}_2) falls below 90%90\%; hyperoxia in normoxic patients causes coronary vasoconstriction and is associated with increased myocardial injury and mortality. Intravenous morphine (11 to 5 mg5\,\text{mg} every 55 to 30 minutes30\,\text{minutes}) provides analgesia and venodilation for refractory chest pain (Class IIb), but observational analyses (such as the CRUSADE registry) link morphine use to increased mortality, and pharmacokinetic studies demonstrate that morphine delays gastrointestinal absorption and diminishes peak antiplatelet activity of oral P2Y12\text{P2Y}_{12} inhibitors. Oral β\beta-blockers should be initiated within the first 24 hours24\,\text{hours} in the absence of signs of heart failure, low-output states, risk factors for cardiogenic shock (age >70 years> 70\,\text{years}, heart rate >110 beats/min> 110\,\text{beats/min}, systolic blood pressure <120 mm Hg< 120\,\text{mm Hg}, prolonged duration of symptoms), or classic contraindications (PR\text{PR} interval >0.24 s> 0.24\,\text{s}, second- or third-degree heart block, active bronchospastic airway disease). Intravenous β\beta-blockers should not be administered routinely due to an increased risk of cardiogenic shock.

Oral P2Y12\text{P2Y}_{12} receptor antagonists are co-administered with aspirin to establish dual antiplatelet therapy (DAPT\text{DAPT}) in all acute coronary syndrome presentations. Clopidogrel is an oral thienopyridine prodrug requiring two-step hepatic oxidation via cytochrome P450 enzymes (predominantly CYP2C19) to generate its active thiol metabolite, which irreversibly inhibits platelet P2Y12\text{P2Y}_{12} receptors. Clopidogrel requires an oral loading dose of 300300 to 600 mg600\,\text{mg} (600 mg600\,\text{mg} achieves faster, more complete, and more consistent platelet inhibition within 2 hours2\,\text{hours} compared with 6 hours6\,\text{hours} for 300 mg300\,\text{mg}), followed by a maintenance dose of 75 mg75\,\text{mg} daily. Clopidogrel carries a boxed warning regarding loss-of-function CYP2C19 alleles (*2, *3), which result in diminished active metabolite concentrations, attenuated platelet inhibition, and higher post-PCI ischemic and stent thrombosis rates; strong CYP2C19 inhibitors like omeprazole and esomeprazole should be avoided. Prasugrel is a third-generation thienopyridine prodrug rapidly hydrolyzed by intestinal esterases and converted by a single CYP-dependent step into an active metabolite that irreversibly inhibits P2Y12\text{P2Y}_{12} receptors, providing more potent (60%60\% to 70%70\% inhibition) and faster antiplatelet activity (onset within 30 minutes30\,\text{minutes}). Prasugrel is dosed as a 60 mg60\,\text{mg} oral loading dose followed by 10 mg10\,\text{mg} daily (reduced to 5 mg5\,\text{mg} daily for body weight <60 kg< 60\,\text{kg} or age ≥75 years\ge 75\,\text{years}). Prasugrel holds a Class IIa recommendation over clopidogrel in ACS managed with PCI\text{PCI} based on the TRITON-TIMI 38 and ISAR-REACT 5 trials. However, prasugrel is strictly contraindicated in patients with a history of transient ischemic attack (TIA\text{TIA}) or stroke due to a significant increase in intracranial and fatal bleeding; it should not be administered prior to defining coronary anatomy.

Ticagrelor is a direct-acting, reversibly binding, noncompetitive cyclopentyltriazolopyrimidine P2Y12\text{P2Y}_{12} antagonist that does not require metabolic activation. Dosed as a 180 mg180\,\text{mg} oral loading dose followed by 90 mg90\,\text{mg} twice daily, ticagrelor achieves 60%60\% to 70%70\% platelet inhibition within 30 minutes30\,\text{minutes}. The PLATO trial demonstrated superiority over clopidogrel in reducing ischemic events and cardiovascular mortality without increasing overall major bleeding, though non-CABG bleeding was increased. Ticagrelor carries a boxed warning that maintenance aspirin doses exceeding 100 mg/day100\,\text{mg/day} decrease its clinical effectiveness; aspirin must be maintained at 81 mg81\,\text{mg} daily. Adverse effects unique to ticagrelor include dyspnea (10%10\% to 15%15\%; mediated by adenosine reuptake inhibition) and asymptomatic ventricular pauses; caution is advised in severe pulmonary disease. Ticagrelor is contraindicated in active pathologic bleeding, history of intracranial hemorrhage, and severe hepatic impairment. Cangrelor is an intravenous, direct-acting, reversible P2Y12\text{P2Y}_{12} antagonist with a plasma half-life of less than 5 minutes5\,\text{minutes}, achieving greater than 90%90\% platelet inhibition within 5 minutes5\,\text{minutes} when administered as a 30\,\text{\mu g/kg} intravenous bolus followed by a 4\,\text{\mu g/kg/min} continuous infusion for at least 2 hours2\,\text{hours} or the duration of PCI\text{PCI} (CHAMPION PHOENIX). Oral clopidogrel or prasugrel cannot be administered until the cangrelor infusion is terminated because cangrelor blocks their irreversible binding sites; ticagrelor may be loaded immediately before, during, or after cangrelor termination.

Intravenous glycoprotein IIb/IIIa (GP IIb/IIIa\text{GP IIb/IIIa}) receptor inhibitors (eptifibatide and tirofiban) block the final common pathway of platelet aggregation by preventing fibrinogen cross-linking. Routine upstream administration before PCI\text{PCI} is not recommended due to increased bleeding without ischemic benefit; use is restricted to provisional bailout for large intraprocedural thrombus burden, slow-flow/no-reflow phenomena, or acute vessel closure in patients not adequately pretreated with oral P2Y12\text{P2Y}_{12} inhibitors. Eptifibatide is dosed for PCI\text{PCI} as a double bolus of 180\,\text{\mu g/kg} intravenously 10 minutes10\,\text{minutes} apart, followed by a continuous infusion of 2.0\,\text{\mu g/kg/min} for 1818 to 24 hours24\,\text{hours}; if creatinine clearance (CrCl\text{CrCl}) is less than 50 mL/min50\,\text{mL/min}, the infusion is reduced by 50%50\% (1.0\,\text{\mu g/kg/min}), and it is avoided in hemodialysis. Tirofiban is dosed as a high-dose bolus of 25\,\text{\mu g/kg} over 3 minutes3\,\text{minutes}, followed by 0.15\,\text{\mu g/kg/min} for 18 hours18\,\text{hours}, with the infusion reduced by 50%50\% for CrCl≤60 mL/min\text{CrCl} \le 60\,\text{mL/min}.

Parenteral anticoagulation is indicated for all ACS patients throughout procedural revascularization. Unfractionated heparin (UFH\text{UFH}) is administered as an initial weight-adjusted bolus of 60 units/kg60\,\text{units/kg} (maximum 4000 units4000\,\text{units}) followed by a continuous infusion of 12 units/kg/hour12\,\text{units/kg/hour} (maximum 1000 units/hour1000\,\text{units/hour}) titrated to institutional activated partial thromboplastin time (aPTT\text{aPTT}) or anti-factor Xa ranges; during PCI\text{PCI}, target activated clotting times (ACT\text{ACT}) are 250250 to 300 seconds300\,\text{seconds} (or 200200 to 250 seconds250\,\text{seconds} if concurrent GP IIb/IIIa\text{GP IIb/IIIa} inhibitors are used). Enoxaparin is dosed at 1 mg/kg1\,\text{mg/kg} subcutaneously every 12 hours12\,\text{hours} in NSTE-ACS\text{NSTE-ACS} (preceded by a 30 mg30\,\text{mg} intravenous bolus in high-risk patients); for PCI\text{PCI}, no supplemental anticoagulation is needed if the last subcutaneous dose was administered within 8 hours8\,\text{hours}, whereas an intravenous booster of 0.3 mg/kg0.3\,\text{mg/kg} is required if the last dose was given 88 to 12 hours12\,\text{hours} prior. If CrCl<30 mL/min\text{CrCl} < 30\,\text{mL/min}, enoxaparin is adjusted to 1 mg/kg1\,\text{mg/kg} subcutaneously once daily. Fondaparinux (2.5 mg2.5\,\text{mg} subcutaneously daily) is a selective factor Xa inhibitor indicated for medical management of NSTE-ACS\text{NSTE-ACS}, but must never be used as the sole anticoagulant during PCI\text{PCI} (Class III: Harm) due to high rates of catheter thrombosis; supplemental UFH\text{UFH} (85 units/kg85\,\text{units/kg}, or 60 units/kg60\,\text{units/kg} with GP IIb/IIIa\text{GP IIb/IIIa} inhibitors) must be co-administered during coronary intervention. Bivalirudin is an intravenous direct thrombin inhibitor dosed for PCI\text{PCI} as a 0.75 mg/kg0.75\,\text{mg/kg} bolus followed by a 1.75 mg/kg/hour1.75\,\text{mg/kg/hour} infusion, reduced to 1.0 mg/kg/hour1.0\,\text{mg/kg/hour} for CrCl<30 mL/min\text{CrCl} < 30\,\text{mL/min} and 0.25 mg/kg/hour0.25\,\text{mg/kg/hour} in hemodialysis. Bivalirudin is the anticoagulant of choice for patients with a documented history of heparin-induced thrombocytopenia (HIT\text{HIT}) undergoing catheterization.

Long-term post-ACS medical therapy requires indefinite daily aspirin (81 mg81\,\text{mg}) and an oral P2Y12\text{P2Y}_{12} inhibitor for at least 12 months12\,\text{months} (Class I), regardless of whether coronary stenting or medical therapy was employed. In patients treated with newer-generation drug-eluting stents (DES\text{DES}), early discontinuation of aspirin after 11 to 3 months3\,\text{months} with continued P2Y12\text{P2Y}_{12} inhibitor monotherapy (ticagrelor or clopidogrel) represents a reasonable strategy (Class IIa) to lower bleeding risks without increasing major adverse cardiovascular events (MACE\text{MACE}). In patients with high bleeding risk, discontinuing the P2Y12\text{P2Y}_{12} inhibitor after 6 months6\,\text{months} while maintaining aspirin is reasonable (Class IIb). Conversely, prolonged DAPT\text{DAPT} beyond 12 months12\,\text{months} (up to 36 months36\,\text{months}) using reduced-dose ticagrelor (60 mg60\,\text{mg} twice daily; PEGASUS-TIMI 54) or clopidogrel is reasonable for patients with high ischemic risk and low bleeding vulnerability. Decision-making is assisted by the validated DAPT score (calculated at 12 months12\,\text{months} post-PCI): a score of 22 or greater favors prolonged DAPT\text{DAPT} by demonstrating a net ischemic benefit, whereas a score below 22 portends an unfavorable risk profile driven by excess bleeding without reduction in ischemic outcomes.

Additional secondary prevention pharmacotherapies include: high-intensity statin therapy (atorvastatin 80 mg80\,\text{mg} daily or rosuvastatin 2020 to 40 mg40\,\text{mg} daily) initiated within 24 hours24\,\text{hours} of presentation, targeting an LDL-C\text{LDL-C} reduction of 50%50\% or greater and an absolute LDL-C<55 mg/dL\text{LDL-C} < 55\,\text{mg/dL}; ACE\text{ACE} inhibitors (or ARBs\text{ARBs}) initiated within 24 hours24\,\text{hours} and continued indefinitely in all patients with an LVEF≤40%\text{LVEF} \le 40\%, hypertension, diabetes, or stable chronic kidney disease; and aldosterone receptor antagonists (eplerenone or spironolactone) indicated in patients already taking an ACE\text{ACE} inhibitor and β\beta-blocker with an LVEF≤40%\text{LVEF} \le 40\% and either clinical heart failure symptoms or diabetes, provided serum potassium is less than 5.0 mEq/L5.0\,\text{mEq/L} and renal function is preserved (SCr≤2.5 mg/dL\text{SCr} \le 2.5\,\text{mg/dL} in men, ≤2.0 mg/dL\le 2.0\,\text{mg/dL} in women, or CrCl≥30 mL/min\text{CrCl} \ge 30\,\text{mL/min}; EPHESUS). For musculoskeletal pain, NSAIDs\text{NSAIDs} and selective COX-2\text{COX-2} inhibitors are strictly avoided (Class III: Harm); a stepped-care analgesic approach utilizing acetaminophen, nonacetylated salicylates, tramadol, or low-dose opioids should be employed.

In patients with atrial fibrillation undergoing PCI\text{PCI}, triple therapy (oral anticoagulant plus aspirin plus a P2Y12\text{P2Y}_{12} inhibitor) significantly magnifies major bleeding and must be minimized. Large randomized clinical trials (WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS) confirmed that double therapy consisting of a direct-acting oral anticoagulant (DOAC\text{DOAC}) and a P2Y12\text{P2Y}_{12} inhibitor (clopidogrel 75 mg75\,\text{mg} daily preferred; avoid prasugrel) without aspirin dramatically reduces major bleeding without increasing stent thrombosis or ischemic events compared to triple therapy. Aspirin is typically discontinued upon hospital discharge or continued for up to 1 month1\,\text{month} in patients with high thrombotic risk; after 12 months12\,\text{months}, antiplatelet therapy is discontinued and DOAC\text{DOAC} monotherapy is maintained indefinitely.

Chronic Coronary Disease and Angina Pectoris

Chronic coronary disease (CCD\text{CCD}) describes stabilized outpatients with a prior history of acute coronary syndrome or coronary revascularization, patients with left ventricular systolic dysfunction or ischemic cardiomyopathy, individuals with stable angina, patients with vasospastic or microvascular angina, and asymptomatic individuals diagnosed via noninvasive imaging or coronary computed tomography angiography (CCTA\text{CCTA}). In the United States, approximately 20.1×10620.1\times 10^6 people live with coronary artery disease, and roughly 11.1×10611.1\times 10^6 carry an active diagnosis of CCD\text{CCD}. Therapeutic goals are twofold: prolong survival by preventing recurrent myocardial infarction, heart failure hospitalizations, and cardiovascular death, and enhance quality of life by preventing anginal symptoms and restoring functional exercise capacity.

Lifestyle interventions require at least 150 minutes/week150\,\text{minutes/week} of moderate-intensity aerobic physical activity or at least 75 minutes/week75\,\text{minutes/week} of vigorous-intensity aerobic exercise, combined with resistance training on at least 2 days/week2\,\text{days/week}. Nutritional guidance mandates adherence to a Mediterranean or DASH\text{DASH} dietary pattern emphasizing fresh fruits, vegetables, legumes, whole grains, nuts, and lean animal or plant proteins, while eliminating industrial trans fats, limiting saturated fats to less than 6%6\% of total daily calories, and restricting dietary sodium to less than 2300 mg/day2300\,\text{mg/day} (optimally <1500 mg/day< 1500\,\text{mg/day}). Over-the-counter dietary supplements, including non-purified omega-3 fish oils, vitamin E, vitamin C, and beta-carotene, lack demonstrated efficacy for cardiovascular event reduction.


Antiplatelet strategies for chronic coronary disease based on clinical history

Antithrombotic therapy in CCD\text{CCD} without an indication for chronic anticoagulation is guided by time elapsed from revascularization and individual ischemic versus bleeding risk. For patients with stable CCD\text{CCD} without recent PCI\text{PCI} (>12 months> 12\,\text{months}) or prior ACS\text{ACS}, single antiplatelet therapy (SAPT\text{SAPT}) with low-dose aspirin (7575 to 100 mg100\,\text{mg} daily, typically 81 mg81\,\text{mg} in the United States) is recommended. The PANTHER individual patient-data meta-analysis established that long-term P2Y12\text{P2Y}_{12} inhibitor monotherapy (predominantly clopidogrel 75 mg75\,\text{mg} daily) provides equivalent bleeding rates and a significant reduction in MACE\text{MACE} compared with aspirin monotherapy, supporting clopidogrel as an effective alternative. Routine addition of clopidogrel to aspirin in patients with stable CCD\text{CCD} lacking recent ACS\text{ACS} or stenting is not recommended due to bleeding risks without clinical benefit. In patients with CCD\text{CCD} at high risk of recurrent ischemic events and low bleeding risk who lack an indication for full anticoagulation or DAPT\text{DAPT}, the addition of vascular-dose rivaroxaban (2.5 mg2.5\,\text{mg} orally twice daily) to aspirin 81 mg81\,\text{mg} daily is reasonable to reduce MACE\text{MACE} based on the COMPASS trial (24%24\% reduction in cardiovascular death, stroke, or myocardial infarction offset by increased major bleeding without significant difference in fatal bleeding).


Antithrombotic pathways in chronic coronary disease requiring chronic anticoagulation

In patients with CCD\text{CCD} who require therapeutic anticoagulation (e.g., for atrial fibrillation or venous thromboembolism) and undergo PCI\text{PCI} with a drug-eluting stent, antithrombotic duration is stratified by clinical risk. In patients with low-to-moderate bleeding risk, triple therapy with a DOAC\text{DOAC}, clopidogrel (75 mg75\,\text{mg} daily), and aspirin (81 mg81\,\text{mg} daily) is restricted to the peri-procedural period (up to 1 month1\,\text{month} post-PCI), transitioning to double therapy (DOAC\text{DOAC} plus clopidogrel) through month 6 or 12, followed by lifelong DOAC\text{DOAC} monotherapy. In patients with high ischemic risk, triple therapy is continued for up to 1 month1\,\text{month}, followed by double therapy through month 6 or 12, and DOAC\text{DOAC} monotherapy beyond 12 months12\,\text{months}. In patients with stable CCD\text{CCD} on therapeutic anticoagulation who did not undergo PCI\text{PCI}, oral anticoagulant monotherapy with a DOAC\text{DOAC} is recommended without antiplatelet co-administration.


Stepwise management algorithm for anginal symptoms in chronic coronary disease

Antianginal medical therapy aims to rebalance myocardial oxygen supply and demand. First-line therapies for symptom control include β\beta-blockers, calcium channel blockers (CCBs\text{CCBs}), or long-acting nitrates. All patients must receive a prescription for sublingual nitroglycerin tablets (0.30.3 to 0.4 mg0.4\,\text{mg}) or nitroglycerin lingual spray for acute symptom termination or situational prophylaxis before exertion. Nitroglycerin lingual spray demonstrates faster mucosal absorption, more reliable clinical efficacy, and fewer tension headaches than sublingual tablets. β\beta-Blockers reduce myocardial oxygen consumption by reducing resting and exercise heart rate, myocardial contractility, and systemic arterial pressure; in patients with a history of myocardial infarction, β\beta-blockers are prioritized during the initial 12 months12\,\text{months} and maintained indefinitely if left ventricular systolic dysfunction (LVEF≤50%\text{LVEF} \le 50\%) or symptomatic heart failure is present. Calcium channel blockers promote epicardial coronary vasodilation and afterload reduction; dihydropyridines (amlodipine, felodipine) are preferred when combined with β\beta-blockers, whereas non-dihydropyridines (diltiazem, verapamil) reduce heart rate and contractility and must be used with caution alongside β\beta-blockers due to risks of sinus arrest and high-grade atrioventricular block. Long-acting oral nitrates (isosorbide mononitrate, isosorbide dinitrate) provide venodilation, lower ventricular preload, and promote coronary collateral blood flow; an eccentric dosing schedule providing a daily nitrate-free interval of 1010 to 14 hours14\,\text{hours} is mandatory to avoid vascular tolerance.

Ranolazine serves as a third-line antianginal agent for patients with persistent symptoms despite optimized β\beta-blocker, CCB\text{CCB}, and nitrate therapy, or as a second-line agent when hemodynamic parameters (bradycardia or hypotension) preclude dose escalation of first-line therapies. Ranolazine selectively inhibits the late phase of the inward sodium current (INa,lateI_{\text{Na,late}}) in ischemic ventricular cardiomyocytes. Attenuating excess intracellular sodium influx prevents reverse-mode activation of the sodium-calcium exchanger (NCX\text{NCX}), decreasing intracellular calcium overload, improving diastolic left ventricular relaxation, reducing microvascular compression, and enhancing myocardial oxygen efficiency without altering heart rate or systemic blood pressure. Ranolazine produces dose-dependent prolongation of the corrected QT (QTc\text{QTc}) interval and is metabolized via CYP3A4 and cleared as a P-glycoprotein (P-gp\text{P-gp}) substrate. It is contraindicated in severe hepatic cirrhosis, and concurrent administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin) or inducers (rifampin, carbamazepine, St. John's wort) is prohibited; when co-administered with moderate CYP3A4 inhibitors (diltiazem, verapamil, fluconazole), the ranolazine dose must not exceed 500 mg500\,\text{mg} twice daily.


Blood pressure control strategies in patients with chronic coronary disease

Blood pressure in CCD\text{CCD} is managed to a goal below 130/80 mm Hg130/80\,\text{mm Hg}. Initial pharmacotherapy combines an ACE\text{ACE} inhibitor or ARB\text{ARB} with an evidence-based β\beta-blocker for patients with recent myocardial infarction, left ventricular systolic dysfunction (LVEF≤40%\text{LVEF} \le 40\%), or active angina. If blood pressure remains elevated (≥130/80 mm Hg\ge 130/80\,\text{mm Hg}), dihydropyridine calcium channel blockers, thiazide-like diuretics (chlorthalidone), or mineralocorticoid receptor antagonists are added sequentially. In patients with CCD\text{CCD} and an LVEF≤50%\text{LVEF} \le 50\%, metoprolol succinate, carvedilol, or bisoprolol are specifically prioritized. In patients with a remote history of myocardial infarction (>12 months> 12\,\text{months}) who lack left ventricular systolic dysfunction (LVEF>50%\text{LVEF} > 50\%), ongoing angina, arrhythmias, or uncontrolled hypertension, the necessity of continuing β\beta-blocker therapy should be reassessed.


Lipid-lowering management algorithm in chronic coronary disease

Lipid management in CCD\text{CCD} dictates that all patients receive maximally tolerated high-intensity statin therapy (atorvastatin 80 mg80\,\text{mg} or rosuvastatin 2020 to 40 mg40\,\text{mg} daily) to achieve a baseline LDL-C\text{LDL-C} reduction of 50%50\% or greater and an absolute LDL-C\text{LDL-C} target below 55 mg/dL55\,\text{mg/dL}. Risk stratification classifies individuals into very high risk if they possess a history of multiple major ASCVD\text{ASCVD} events (recent acute coronary syndrome within 12 months12\,\text{months}, prior myocardial infarction, ischemic stroke, or symptomatic peripheral artery disease) or one major event plus multiple high-risk conditions (age ≥65 years\ge 65\,\text{years}, heterozygous familial hypercholesterolemia, history of prior CABG\text{CABG} or PCI\text{PCI} outside the index event, diabetes mellitus, hypertension, chronic kidney disease with eGFR\text{eGFR} 1515 to 59 mL/min/1.73 m259\,\text{mL/min/1.73}\,\text{m}^2, active tobacco smoking, heart failure, or persistently elevated LDL-C≥100 mg/dL\text{LDL-C} \ge 100\,\text{mg/dL} despite statins and ezetimibe). If LDL-C\text{LDL-C} remains at or above 70 mg/dL70\,\text{mg/dL} on maximally tolerated statin therapy, ezetimibe (10 mg10\,\text{mg} daily) is added; if LDL-C\text{LDL-C} remains at or above 70 mg/dL70\,\text{mg/dL} or non-HDL-C is 100 mg/dL100\,\text{mg/dL} or greater on statin plus ezetimibe, a proprotein convertase subtilisin/kexin type 9 (PCSK9\text{PCSK9}) monoclonal antibody (evolocumab or alirocumab) should be initiated. For patients with statin intolerance or inadequate response, bempedoic acid (which demonstrated significant MACE\text{MACE} reduction in the CLEAR Outcomes trial) or inclisiran may be incorporated. When fasting triglycerides remain elevated (150150 to 499 mg/dL499\,\text{mg/dL}) despite statin therapy, icosapent ethyl (2 g2\,\text{g} twice daily with meals) is added to reduce ischemic cardiovascular events (REDUCE-IT).

Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 (GLP-1\text{GLP-1}) receptor agonists confer cardioprotective benefits in patients with CCD\text{CCD}. SGLT2 inhibitors carry a strong recommendation in patients with concurrent type 2 diabetes or heart failure (irrespective of ejection fraction) to reduce MACE\text{MACE}, cardiovascular death, and heart failure hospitalizations. GLP-1 receptor agonists (such as subcutaneous semaglutide and liraglutide) are recommended in patients with CCD\text{CCD} and type 2 diabetes to decrease MACE\text{MACE}, and are indicated as adjuncts for weight reduction in patients with overweight or obesity to improve metabolic control and reduce cardiovascular risk. Secondary prevention also incorporates routine immunizations (annual influenza, pneumococcal, and COVID-19 vaccinations), anti-inflammatory secondary prevention with low-dose colchicine (0.5 mg0.5\,\text{mg} daily) to suppress atherothrombotic events, complete tobacco cessation, elimination of excess alcohol, and structured screening and treatment for clinical depression.

Atrial Fibrillation and Arrhythmia Management

Atrial fibrillation (AF\text{AF}) represents the most common sustained cardiac arrhythmia encountered in clinical practice, affecting over 2.2×1062.2\times 10^6 Americans. The arrhythmia is characterized electrophysiologically by rapid, disorganized, and chaotic atrial activation, resulting in mechanical dyssynchrony of the atrial myocardium and an irregularly irregular ventricular response.


Normal cardiac conduction system and atrial fibrillation mechanisms

In normal cardiac conduction, the cardiac impulse originates spontaneously in the sinoatrial (SA\text{SA}) node located in the superior right atrium, propagates across atrial tissue, pauses within the atrioventricular (AV\text{AV}) node to ensure ventricular filling, traverses the bundle of His, bifurcates down the right and left bundle branches, and rapidly distributes through the subendocardial Purkinje arborization to activate ventricular myocardium. In atrial fibrillation, multiple disorganized wavelets of functional reentry or rapidly firing ectopic foci (most commonly originating within the muscular sleeves of the pulmonary veins in the left atrium) bombard the AV\text{AV} node at rates ranging from 400400 to 600 impulses/min600\,\text{impulses/min}. The AV\text{AV} node acts as a physiological filter; its decremental conduction and variable refractory period permit only a fraction of these chaotic impulses to activate the ventricles, yielding an irregularly irregular ventricular response and an absent atrial "kick," which reduces cardiac output by 15%15\% to 30%30\%.


Electrocardiographic tracing demonstrating atrial fibrillation

Electrocardiographic hallmarks of atrial fibrillation consist of an irregularly irregular R-R\text{R-R} interval pattern, the absence of distinct, uniform P waves, and their replacement by rapid, irregular fibrillatory (f) waves varying in amplitude, morphology, and timing. Clinical classifications define paroxysmal AF\text{AF} as recurrent episodes that terminate spontaneously or with intervention within 7 days7\,\text{days} of onset; persistent AF\text{AF} as continuous episodes lasting longer than 7 days7\,\text{days}; long-standing persistent AF\text{AF} as continuous episodes exceeding 12 months12\,\text{months} where a rhythm control strategy is maintained; and permanent AF\text{AF} where patient and clinician mutually decide to cease further rhythm restoration attempts, accepting the arrhythmia as permanent. Nonvalvular AF\text{AF} is clinically defined by the absence of moderate-to-severe mitral stenosis or a mechanical prosthetic heart valve. Predisposing etiologies encompass conditions causing atrial stretch or structural remodeling (chronic hypertension, mitral or tricuspid valvular disease, cardiomyopathies, pulmonary hypertension, acute pulmonary embolism, obstructive sleep apnea, chronic obstructive pulmonary disease) and triggers of hyperadrenergic tone (thyrotoxicosis, sepsis, alcohol intoxication or withdrawal, major cardiothoracic surgery, and sympathomimetic exposures).

Initial pharmacotherapy addresses ventricular rate control. Resting heart rate targets are stratified: a strict rate-control goal (<80 beats/min< 80\,\text{beats/min} at rest) is reasonable for symptomatic patients (Class IIa), whereas a lenient rate-control strategy (<110 beats/min< 110\,\text{beats/min} at rest) is acceptable for asymptomatic patients with preserved ejection fraction (AFFIRM, RACE; Class IIb). First-line rate-controlling agents include β\beta-blockers and non-dihydropyridine calcium channel blockers (CCBs\text{CCBs}). β\beta-Blockers (metoprolol, carvedilol, atenolol, bisoprolol) slow AV\text{AV} nodal conduction velocity and prolong refractory periods, performing effectively during physical exertion and hyperadrenergic states; carvedilol, metoprolol succinate, and bisoprolol are specifically indicated in patients with comorbid HFrEF\text{HFrEF}. Non-dihydropyridine CCBs\text{CCBs} (diltiazem, verapamil) inhibit L-type calcium channels within the AV\text{AV} node to provide rate control during rest and exercise, making them useful in chronic obstructive pulmonary disease or asthma, but are contraindicated in left ventricular systolic dysfunction (LVEF≤40%\text{LVEF} \le 40\%) due to negative inotropic effects. Digoxin slows AV\text{AV} nodal conduction primarily via central vagomimetic effects; it is ineffective as monotherapy for rate control during exercise due to high sympathetic tone, but serves as a useful adjunctive agent in HFrEF\text{HFrEF} or sedentary patients. Intravenous amiodarone is reserved for acute rate control in patients with critical illness, severe left ventricular systolic dysfunction, or heart failure without an accessory pathway when alternative agents are ineffective or contraindicated.

A rhythm control strategy aims to restore and maintain normal sinus rhythm through electrical or pharmacologic cardioversion, antiarrhythmic drug (AAD\text{AAD}) therapy, or catheter ablation. The EAST-AFNET 4 trial established that early rhythm control initiated within 12 months12\,\text{months} of AF\text{AF} diagnosis in patients with cardiovascular comorbidities resulted in a significant reduction in cardiovascular death, stroke, and heart failure hospitalizations compared with rate control alone. Pharmacologic cardioversion is achieved using Vaughan-Williams Class Ic (flecainide, propafenone) or Class III (amiodarone, dofetilide, ibutilide) antiarrhythmic agents.

Cardioversion carries an inherent risk of thromboembolism due to the mobilization of pre-existing atrial thrombi or post-cardioversion atrial stunning. For patients presenting with atrial fibrillation of 48 hours48\,\text{hours} or greater duration, or when the duration is unknown, therapeutic anticoagulation must be administered continuously for at least 3 weeks3\,\text{weeks} prior to elective cardioversion, followed by mandatory therapeutic anticoagulation for at least 4 weeks4\,\text{weeks} post-cardioversion, irrespective of the patient's baseline stroke risk score. Alternatively, an expedited transesophageal echocardiogram (TEE\text{TEE}) strategy may be employed: full therapeutic anticoagulation (using unfractionated heparin, low-molecular-weight heparin, or a DOAC\text{DOAC}) is initiated, and if TEE\text{TEE} confirms the absence of thrombus in the left atrium and left atrial appendage, cardioversion is executed within 24 hours24\,\text{hours}, followed by at least 4 weeks4\,\text{weeks} of therapeutic oral anticoagulation. For hemodynamically unstable atrial fibrillation (severe hypotension, cardiogenic shock, acute pulmonary edema, ongoing myocardial ischemia), immediate synchronized direct-current cardioversion is indicated, with therapeutic parenteral anticoagulation administered immediately prior to the shock and maintained for at least 4 weeks4\,\text{weeks} post-procedure.

Antiarrhythmic drug selection is dictated by the presence or absence of underlying structural heart disease (defined as coronary artery disease, prior myocardial infarction, left ventricular hypertrophy, or heart failure). Class Ic agents (flecainide and propafenone) exhibit fast sodium channel blockade with slow dissociation kinetics, slowing conduction velocity without prolonging the refractory period or the QT interval. In the absence of structural heart disease, flecainide (5050 to 150 mg150\,\text{mg} twice daily) and propafenone (150150 to 300 mg300\,\text{mg} every 88 to 12 hours12\,\text{hours}, or extended-release 225225 to 425 mg425\,\text{mg} twice daily) provide 80%80\% to 90%90\% efficacy for sinus rhythm maintenance; a "pill-in-the-pocket" strategy utilizing a single oral dose of flecainide (200200 to 300 mg300\,\text{mg}) or propafenone (450450 to 600 mg600\,\text{mg}) can terminate paroxysmal out-of-hospital episodes. Class Ic agents can convert atrial fibrillation into rapid atrial flutter with 1:1 AV1:1\,\text{AV} conduction; therefore, concomitant AV\text{AV} nodal blocking agents (β\beta-blockers or non-dihydropyridine CCBs\text{CCBs}) must be prescribed. Class Ic agents are strictly contraindicated in structural heart disease or ischemic coronary disease based on the CAST trial, which demonstrated increased mortality driven by fatal ventricular proarrhythmias.

Class III antiarrhythmics block delayed rectifier potassium channels to prolong action potential duration and effective refractoriness, manifesting on the surface ECG\text{ECG} as QT interval prolongation. Amiodarone exhibits multichannel electrophysiologic properties (Classes I, II, III, IV) and represents the most effective agent for sinus rhythm maintenance (85%85\% to 95%95\% efficacy). Because of its neutral mortality profile in left ventricular systolic dysfunction, amiodarone is safe in coronary disease and heart failure. Oral loading requires cumulative administration of 66 to 10 g10\,\text{g} (typically 400 mg400\,\text{mg} two to three times daily for 2 weeks2\,\text{weeks}, followed by 400 mg400\,\text{mg} daily for 4 weeks4\,\text{weeks}, then 200 mg200\,\text{mg} daily maintenance). Its terminal elimination half-life averages approximately 5858 to 60 days60\,\text{days}, reflecting extensive lipophilic tissue sequestration. Amiodarone is a potent inhibitor of CYP3A4, CYP2C9, CYP2D6, CYP1A2, and P-glycoprotein, requiring empiric dose reductions of concomitant warfarin (decrease by 33%33\% to 50%50\%), digoxin (decrease by 50%50\%), simvastatin (maximum daily dose 20 mg20\,\text{mg}), and lovastatin (maximum daily dose 40 mg40\,\text{mg}). Extracardiac organ toxicities require baseline and periodic surveillance: serum transaminases and thyroid function panels every 6 months6\,\text{months}; annual chest radiography; baseline pulmonary function testing with diffusing capacity of the lungs for carbon monoxide (DLCO\text{DLCO}) repeated for unexplained cough or dyspnea (pulmonary toxicity/interstitial pneumonitis); ophthalmologic exams for visual changes (corneal microdeposits, optic neuritis); and monitoring for photosensitivity, blue-gray skin discoloration, peripheral neuropathy, and ataxia.

Sotalol is a nonselective β\beta-blocker with class III potassium channel blocking properties (50%/50%50\%/50\% activity), indicated for sinus rhythm maintenance in patients with coronary disease or hypertension without significant left ventricular hypertrophy or heart failure. Sotalol is contraindicated in heart failure (LVEF<40%\text{LVEF} < 40\%), baseline QTc>440 ms\text{QTc} > 440\,\text{ms}, and CrCl<40 mL/min\text{CrCl} < 40\,\text{mL/min}. Initiation requires a mandatory minimum 3 day3\,\text{day} hospitalization with continuous telemetry monitoring and serial ECGs\text{ECGs}. Dosing is adjusted for creatinine clearance: 80 mg80\,\text{mg} twice daily for CrCl>60 mL/min\text{CrCl} > 60\,\text{mL/min}, and 80 mg80\,\text{mg} once daily for CrCl\text{CrCl} 4040 to 60 mL/min60\,\text{mL/min}. If the QTc\text{QTc} exceeds 500 ms500\,\text{ms} during therapy, the dose must be decreased or the drug discontinued to avoid torsades de pointes.

Dofetilide is a pure selective blocker of the rapid component of the delayed rectifier potassium current (IKrI_{\text{Kr}}), devoid of negative inotropic or hemodynamic effects, making it safe for sinus rhythm restoration and maintenance in heart failure and coronary disease. Dofetilide requires mandatory inpatient initiation for a minimum of 3 days3\,\text{days} (5 doses) with continuous cardiac telemetry and renal surveillance. Starting doses are calculated strictly from estimated creatinine clearance: 500\,\text{\mu g} orally twice daily for CrCl>60 mL/min\text{CrCl} > 60\,\text{mL/min}; 250\,\text{\mu g} twice daily for CrCl\text{CrCl} 4040 to 60 mL/min60\,\text{mL/min}; 125\,\text{\mu g} twice daily for CrCl\text{CrCl} 2020 to 39 mL/min39\,\text{mL/min}; and contraindicated for CrCl<20 mL/min\text{CrCl} < 20\,\text{mL/min}. Baseline QTc\text{QTc} must not exceed 440 ms440\,\text{ms} (500 ms500\,\text{ms} in intraventricular conduction delays). A repeat ECG\text{ECG} must be obtained 22 to 3 hours3\,\text{hours} following the initial dose; if the QTc\text{QTc} increases by greater than 15%15\% over baseline or exceeds 500 ms500\,\text{ms} (550 ms550\,\text{ms} in ventricular conduction delay), the dose must be reduced by 50%50\%. If the QTc\text{QTc} exceeds 500 ms500\,\text{ms} at any check during subsequent doses, the drug must be discontinued. Dofetilide is cleared via renal cationic transport; co-administration is contraindicated with cimetidine, verapamil, hydrochlorothiazide, trimethoprim (alone or with sulfamethoxazole), ketoconazole, itraconazole, prochlorperazine, megestrol, and dolutegravir.

Dronedarone is a non-iodinated synthetic derivative of amiodarone that undergoes CYP3A4 hepatic clearance with an elimination half-life of 1313 to 19 hours19\,\text{hours}. Dosed at 400 mg400\,\text{mg} orally twice daily with morning and evening meals, dronedarone reduces cardiovascular hospitalizations in paroxysmal or persistent AF\text{AF}. Dronedarone carries boxed warnings and is strictly contraindicated in patients with permanent atrial fibrillation (PALLAS trial; doubled risk of stroke, heart failure hospitalizations, and cardiovascular death) and in symptomatic heart failure with recent decompensation or NYHA\text{NYHA} Class IV symptoms (ANDROMEDA trial; doubled mortality). Dronedarone inhibits tubular creatinine secretion, producing a benign, reversible rise in serum creatinine of approximately 0.1 mg/dL0.1\,\text{mg/dL} without reducing true glomerular filtration.

Thromboembolic risk stratification in nonvalvular atrial fibrillation utilizes the validated CHA2DS2-VASc\text{CHA}_2\text{DS}_2\text{-VASc} score:

  • Congestive heart failure or LVEF≤40%\text{LVEF} \le 40\%: 1 point1\,\text{point}

  • Hypertension: 1 point1\,\text{point}

  • Age 75 years75\,\text{years} or older: 2 points2\,\text{points}

  • Diabetes mellitus: 1 point1\,\text{point}

  • Stroke, TIA\text{TIA}, or systemic thromboembolism: 2 points2\,\text{points}

  • Vascular disease (prior myocardial infarction, peripheral arterial disease, or complex aortic plaque): 1 point1\,\text{point}

  • Age 6565 to 74 years74\,\text{years}: 1 point1\,\text{point}

  • Sex category (female): 1 point1\,\text{point}

For patients with a CHA2DS2-VASc\text{CHA}_2\text{DS}_2\text{-VASc} score of 00 in men or 11 in women, it is reasonable to omit oral anticoagulant therapy. For a score of 11 in men or 22 in women, oral anticoagulation may be considered based on clinical shared decision-making. For a score of 22 or greater in men or 33 or greater in women, chronic oral anticoagulation is indicated (Class I). Direct-acting oral anticoagulants (DOACs\text{DOACs}: dabigatran 150 mg150\,\text{mg} twice daily; rivaroxaban 20 mg20\,\text{mg} once daily with the evening meal; apixaban 5 mg5\,\text{mg} twice daily, or 2.5 mg2.5\,\text{mg} twice daily if any two of: age ≥80 years\ge 80\,\text{years}, body weight ≤60 kg\le 60\,\text{kg}, or serum creatinine ≥1.5 mg/dL\ge 1.5\,\text{mg/dL}; edoxaban 60 mg60\,\text{mg} once daily) are recommended over warfarin due to superior efficacy, lower rates of intracranial hemorrhage, and absent dietary monitoring requirements. Warfarin (titrated to an INR\text{INR} of 2.02.0 to 3.03.0) remains the agent of choice for valvular atrial fibrillation (moderate-to-severe mitral stenosis or mechanical heart valves).

Acute Life-Threatening Arrhythmias and Cardiac Arrest

Adult cardiac arrest management follows the Advanced Cardiovascular Life Support (ACLS\text{ACLS}) algorithmic framework, dividing arrest presentations into shockable rhythms (ventricular fibrillation [VF\text{VF}] and pulseless ventricular tachycardia [pVT\text{pVT}]) and non-shockable rhythms (asystole and pulseless electrical activity [PEA\text{PEA}]). Resuscitation requires immediate cardiopulmonary resuscitation (CPR\text{CPR}) with chest compressions delivered at a rate of 100100 to 120 compressions/min120\,\text{compressions/min} and a depth of 55 to 6 cm6\,\text{cm}, minimizing interruptions, avoiding hyperventilation, and providing high-flow oxygen.

For shockable rhythms (VF/pVT\text{VF/pVT}), an initial asynchronous defibrillation shock is delivered (120120 to 200 J200\,\text{J} for biphasic waveforms, or 360 J360\,\text{J} for monophasic), followed immediately by 2 minutes2\,\text{minutes} of continuous CPR\text{CPR} without pausing for rhythm checks. Following the second defibrillation shock, epinephrine (1 mg1\,\text{mg} intravenously or intraosseously) is administered every 33 to 5 minutes5\,\text{minutes}. If ventricular fibrillation or pulseless ventricular tachycardia persists following the third defibrillation shock, an antiarrhythmic drug is administered: amiodarone is the drug of choice, dosed as a first intravenous bolus of 300 mg300\,\text{mg} diluted in 20 mL20\,\text{mL} of 5%5\% dextrose in water (D5W\text{D}_5\text{W}) or normal saline, with an optional repeat bolus of 150 mg150\,\text{mg} administered once for refractory shockable arrest. If amiodarone is unavailable, lidocaine serves as an alternative, dosed at 1.01.0 to 1.5 mg/kg1.5\,\text{mg/kg} intravenous push initial bolus, followed by repeat doses of 0.50.5 to 0.75 mg/kg0.75\,\text{mg/kg} every 55 to 10 minutes10\,\text{minutes} up to a maximum cumulative dose of 3.0 mg/kg3.0\,\text{mg/kg}. For non-shockable rhythms (asystole/PEA\text{asystole/PEA}), immediate defibrillation is not indicated; management focuses on continuous high-quality CPR\text{CPR}, rapid intravenous/intraosseous administration of epinephrine 1 mg1\,\text{mg} every 33 to 5 minutes5\,\text{minutes}, and prompt identification and reversal of underlying etiologies (the "H's and T's": hypovolemia, hypoxia, hydrogen ion acidosis, hypokalemia or hyperkalemia, hypothermia, tension pneumothorax, cardiac tamponade, toxins, pulmonary thrombosis, and coronary thrombosis).

Post-resuscitation care for comatose adult patients who achieve return of spontaneous circulation (ROSC\text{ROSC}) incorporates Targeted Temperature Management (TTM\text{TTM}) to optimize neurological recovery. Clinical guidelines recommend maintaining a constant core body temperature between 32∘C32^\circ\text{C} and 36∘C36^\circ\text{C} (or strict active normothermia avoiding fever, supported by TTM and TTM2 trials) for at least 24 hours24\,\text{hours}, followed by controlled rewarming at a rate of 0.3∘C/hour0.3^\circ\text{C/hour}. Thermoregulatory shivering, which increases metabolic heat production by up to 600%600\% and elevates systemic oxygen consumption, must be controlled using buspirone, meperidine, clonidine, dexmedetomidine, or neuromuscular blocking infusions. Deep sedation and analgesia are maintained using continuous fentanyl, midazolam, or propofol. Induced hypothermia impairs insulin secretion and peripheral sensitivity (requiring insulin infusions to maintain glycemic targets of 140140 to 180 mg/dL180\,\text{mg/dL}), suppresses renal tubular reabsorption (causing cold diuresis and hypokalemia during cooling, with rebound hyperkalemia during rewarming), and impairs enzymatic clotting pathways, demanding surveillance of platelet counts, PT/INR\text{PT/INR}, and aPTT\text{aPTT}.

In acute symptomatic bradycardia, unstable signs (hypotension, acutely altered mental status, ischemic chest discomfort, acute pulmonary edema, or cardiogenic shock) warrant immediate administration of atropine (1 mg1\,\text{mg} intravenously every 33 to 5 minutes5\,\text{minutes}, up to a maximum cumulative dose of 3 mg3\,\text{mg}). If atropine is ineffective or contraindicated (e.g., in Mobitz Type II second-degree or third-degree atrioventricular block with wide QRS\text{QRS}, or denervated heart post-transplantation), transcutaneous pacing should be initiated immediately, supported by continuous infusions of dopamine (55 to 20\,\text{\mu g/kg/min}) or epinephrine (22 to 10\,\text{\mu g/min}) titrated to chronotropic and hemodynamic response.

In acute symptomatic tachycardia, unstable manifestations mandate emergent synchronized electrical cardioversion. In stable tachycardia, management is stratified by QRS\text{QRS} duration. Narrow-complex tachycardia (QRS<120 ms\text{QRS} < 120\,\text{ms}) with a regular rhythm represents supraventricular tachycardia (SVT\text{SVT}) or sinus tachycardia, treated initially with vagal maneuvers followed by rapid intravenous administration of adenosine: 6 mg6\,\text{mg} rapid intravenous push through a large peripheral vein followed immediately by a 20 mL20\,\text{mL} saline flush and arm elevation; if sinus conversion does not occur within 11 to 2 minutes2\,\text{minutes}, a second dose of 12 mg12\,\text{mg} is administered (repeatable once). The initial dose of adenosine is reduced to 3 mg3\,\text{mg} in patients receiving dipyridamole or carbamazepine, in heart transplant recipients, or when administering via a central venous catheter; higher doses may be needed in the presence of methylxanthines (theophylline, caffeine). Adenosine is contraindicated in severe bronchospastic asthma and must never be administered for irregular or polymorphic wide-complex tachycardia due to the risk of precipitating ventricular fibrillation. Regular narrow-complex SVT\text{SVT} refractory to adenosine is managed with intravenous non-dihydropyridine CCBs\text{CCBs} (diltiazem 0.25 mg/kg0.25\,\text{mg/kg} IV over 2 minutes2\,\text{minutes}, followed by 55 to 15 mg/hour15\,\text{mg/hour}) or intravenous β\beta-blockers (esmolol, metoprolol).

Wide-complex tachycardia (QRS≥120 ms\text{QRS} \ge 120\,\text{ms}) should be treated as ventricular tachycardia (VT\text{VT}) until proven otherwise. Stable monomorphic VT\text{VT} is managed with intravenous antiarrhythmic infusions: procainamide (20 mg/min20\,\text{mg/min} IV infusion up to a maximum loading dose of 17 mg/kg17\,\text{mg/kg}, discontinued if the arrhythmia terminates, severe hypotension occurs, or QRS\text{QRS} widens by >50%> 50\%; maintenance 11 to 4 mg/min4\,\text{mg/min}), amiodarone (150 mg150\,\text{mg} IV over 10 minutes10\,\text{minutes}, repeated as needed, followed by 1.0 mg/min1.0\,\text{mg/min} for 6 hours6\,\text{hours}, then 0.5 mg/min0.5\,\text{mg/min} for 18 hours18\,\text{hours}), or sotalol (100 mg100\,\text{mg} IV over 5 minutes5\,\text{minutes}). Procainamide is contraindicated in severe heart failure (LVEF<40%\text{LVEF} < 40\%) or baseline prolonged QT; sotalol is contraindicated in heart failure or QTc>440 ms\text{QTc} > 440\,\text{ms}. In pre-excited atrial fibrillation (Wolff-Parkinson-White syndrome with antegrade conduction down an accessory pathway), all AV\text{AV} nodal blocking agents (β\beta-blockers, diltiazem, verapamil, digoxin, adenosine) are strictly contraindicated because preferential conduction down the accessory pathway can accelerate the ventricular rate and degenerate into ventricular fibrillation; intravenous procainamide is the drug of choice. Polymorphic ventricular tachycardia associated with a prolonged baseline QT interval (torsades de pointes) is managed in stable patients with intravenous magnesium sulfate (11 to 2 g2\,\text{g} IV diluted in 100 mL100\,\text{mL} D5WD_5W over 15 minutes15\,\text{minutes}, repeatable up to 16 g16\,\text{g} per 24 hours24\,\text{hours}), correction of hypokalemia (K+>4.5\text{K}^+ > 4.5 to 5.0 mEq/L5.0\,\text{mEq/L}), withdrawal of offending QT-prolonging medications, and overdrive pacing; unstable polymorphic VT\text{VT} requires immediate unsynchronized defibrillation.

Hypertension: Chronic Management and Hypertensive Crises

Hypertension is defined as a persistent, nonphysiologic elevation of systemic arterial pressure, specifically a systolic blood pressure (SBP\text{SBP}) of 130 mm Hg130\,\text{mm Hg} or greater, or a diastolic blood pressure (DBP\text{DBP}) of 80 mm Hg80\,\text{mm Hg} or greater. Approximately 46%46\% of adult Americans are affected, establishing hypertension as a leading modifiable risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, and vascular mortality. Essential (primary) hypertension accounts for 90%90\% of all clinical diagnoses, arising from complex multifactorial interactions between genetic susceptibility and environmental factors (obesity, excess dietary sodium, physical inactivity). Secondary hypertension accounts for approximately 10%10\% of cases and must be investigated in severe, resistant, or abrupt-onset disease; primary causes include primary aldosteronism, renal parenchymal disease, renovascular hypertension (renal artery stenosis), obstructive sleep apnea, Cushing syndrome, hyperthyroidism or hypothyroidism, hyperparathyroidism, pheochromocytoma, and medications (cyclosporine, tacrolimus, NSAIDs\text{NSAIDs}, oral contraceptives containing estrogen, systemic corticosteroids, sympathomimetics, and angiogenesis inhibitors).

Diagnosis requires proper measurement methodology. Patients must remain seated quietly in a chair with back supported and feet flat on the floor for at least 5 minutes5\,\text{minutes}, refraining from caffeine, exercise, and smoking for at least 30 minutes30\,\text{minutes} prior to testing. An appropriately sized cuff must be used (bladder length encircling at least 80%80\% of arm circumference and width encircling at least 40%40\%). Blood pressure must be obtained at least twice, separated by at least 2 minutes2\,\text{minutes}, and averaged. Establishing a formal diagnosis requires documenting elevated average readings across two or more separate clinical encounters. Out-of-office blood pressure confirmation using 24-hour ambulatory blood pressure monitoring (ABPM\text{ABPM}) or home blood pressure monitoring (HBPM\text{HBPM}) is recommended to identify white-coat hypertension (office BP\text{BP} 130/80130/80 to 160/100 mm Hg160/100\,\text{mm Hg}, but daytime ABPM\text{ABPM} or HBPM\text{HBPM} <130/80 mm Hg< 130/80\,\text{mm Hg} after a 3 month3\,\text{month} lifestyle trial) and masked hypertension (office BP\text{BP} 120120 to 129/<80 mm Hg129/< 80\,\text{mm Hg}, but daytime out-of-office BP≥130/80 mm Hg\text{BP} \ge 130/80\,\text{mm Hg}).

Nonpharmacologic lifestyle modifications provide substantial, dose-dependent reductions in systolic blood pressure and are recommended for all clinical categories: maintaining a normal body mass index (BMI\text{BMI} 18.518.5 to 24.9 kg/m224.9\,\text{kg/m}^2) reduces SBP\text{SBP} by 55 to 20 mm Hg20\,\text{mm Hg} per 10 kg10\,\text{kg} of weight loss; adopting the Dietary Approaches to Stop Hypertension (DASH\text{DASH}) diet (rich in fruits, vegetables, low-fat dairy products, and dietary potassium, with reduced saturated and total fat) reduces SBP\text{SBP} by 88 to 14 mm Hg14\,\text{mm Hg}; reducing dietary sodium consumption to less than 1500 mg/day1500\,\text{mg/day} (or a minimum reduction of 1000 mg/day1000\,\text{mg/day}) lowers SBP\text{SBP} by 22 to 8 mm Hg8\,\text{mm Hg}; participating in structured aerobic exercise (at least 30 minutes/day30\,\text{minutes/day} of brisk walking most days) reduces SBP\text{SBP} by 44 to 9 mm Hg9\,\text{mm Hg}; and moderating alcohol consumption (limiting intake to 22 or fewer standard drinks daily in men and 11 or fewer standard drinks daily in women) reduces SBP\text{SBP} by 22 to 4 mm Hg4\,\text{mm Hg}.

The 2017 ACC/AHA\text{ACC/AHA} guidelines define four blood pressure categories in adults:

  • Normal: SBP<120 mm Hg\text{SBP} < 120\,\text{mm Hg} and DBP<80 mm Hg\text{DBP} < 80\,\text{mm Hg}

  • Elevated: SBP\text{SBP} 120120 to 129 mm Hg129\,\text{mm Hg} and DBP<80 mm Hg\text{DBP} < 80\,\text{mm Hg}

  • Stage 1 Hypertension: SBP\text{SBP} 130130 to 139 mm Hg139\,\text{mm Hg} or DBP\text{DBP} 8080 to 89 mm Hg89\,\text{mm Hg}

  • Stage 2 Hypertension: SBP≥140 mm Hg\text{SBP} \ge 140\,\text{mm Hg} or DBP≥90 mm Hg\text{DBP} \ge 90\,\text{mm Hg}


Algorithmic treatment strategy for hypertension stratified by ASCVD risk

Thresholds for initiating pharmacotherapy and blood pressure targets are defined by clinical cardiovascular disease status and calculated risk. For patients with established clinical CVD\text{CVD} or a calculated 10-year ASCVD\text{ASCVD} risk of 10%10\% or greater, the threshold for pharmacotherapy is a blood pressure of 130/80 mm Hg130/80\,\text{mm Hg} or greater, with a treatment goal of less than 130/80 mm Hg130/80\,\text{mm Hg}. For individuals without clinical CVD\text{CVD} whose 10-year ASCVD\text{ASCVD} risk is below 10%10\%, the threshold is 140/90 mm Hg140/90\,\text{mm Hg} or greater, with a treatment goal of less than 130/80 mm Hg130/80\,\text{mm Hg}. Compelling comorbid conditions—including diabetes mellitus, chronic kidney disease, post-renal transplantation, heart failure, and stable ischemic heart disease—mandate a threshold of 130/80 mm Hg130/80\,\text{mm Hg} or greater and a goal below 130/80 mm Hg130/80\,\text{mm Hg}. For ambulatory, noninstitutionalized community-dwelling adults aged 65 years65\,\text{years} or older, the treatment threshold is an SBP\text{SBP} of 130 mm Hg130\,\text{mm Hg} or greater, targeting an SBP\text{SBP} below 130 mm Hg130\,\text{mm Hg}, supported by the SPRINT trial where intensive SBP\text{SBP} lowering (<120 mm Hg< 120\,\text{mm Hg} vs. <140 mm Hg< 140\,\text{mm Hg}) reduced primary composite major cardiovascular events and all-cause mortality, even among patients older than 75 years75\,\text{years}.

Pharmacologic selection for Stage 1 hypertension with an indication for treatment typically begins with a single first-line agent selected from four primary classes: thiazide or thiazide-like diuretics, dihydropyridine calcium channel blockers, ACE\text{ACE} inhibitors, or ARBs\text{ARBs}. In adults presenting with Stage 2 hypertension and an average blood pressure greater than 20/10 mm Hg20/10\,\text{mm Hg} above target, initial pharmacotherapy should combine two first-line agents of different classes, administered as separate components or a fixed-dose combination. Specific comorbidity-directed indications apply: in chronic kidney disease with albuminuria (≥300 mg/day\ge 300\,\text{mg/day} or ≥300 mg/g\ge 300\,\text{mg/g} albumin-to-creatinine ratio), ACE\text{ACE} inhibitors or ARBs\text{ARBs} are preferred first-line agents to slow renal disease progression; in diabetes with persistent albuminuria, ACE\text{ACE} inhibitors or ARBs\text{ARBs} are indicated; in Black adults without heart failure or chronic kidney disease, initial therapy should include a thiazide-type diuretic or a calcium channel blocker due to enhanced blood pressure lowering efficacy compared to RAAS\text{RAAS} monotherapy; in pregnant women, preferred agents are oral labetalol, nifedipine extended-release, or methyldopa, while ACE\text{ACE} inhibitors, ARBs\text{ARBs}, and direct renin inhibitors (aliskiren) are contraindicated due to severe fetotoxicity and congenital malformations.

Resistant hypertension is defined as an office blood pressure of 130/80 mm Hg130/80\,\text{mm Hg} or greater in a patient confirmed adherent to at least three antihypertensive medications of different pharmacologic classes at optimal doses, one of which must be a diuretic; or an office blood pressure controlled to less than 130/80 mm Hg130/80\,\text{mm Hg} requiring four or more concurrent antihypertensive drugs. Evaluation mandates exclusion of pseudoresistance (inaccurate cuff sizing, white-coat effect, medication nonadherence) and identification of interfering substances (NSAIDs\text{NSAIDs}, oral decongestants, systemic steroids, cocaine, amphetamines). Pharmacologic optimization of resistant hypertension requires maximizing diuretic efficacy: substituting chlorthalidone or indapamide for hydrochlorothiazide in patients with preserved renal function (eGFR>30 mL/min/1.73 m2\text{eGFR} > 30\,\text{mL/min/1.73}\,\text{m}^2) due to longer half-lives and enhanced natriuresis, or switching to loop diuretics (furosemide, torsemide) if eGFR<30 mL/min/1.73 m2\text{eGFR} < 30\,\text{mL/min/1.73}\,\text{m}^2. The definitive next pharmacologic step is the addition of a mineralocorticoid receptor antagonist (spironolactone 12.512.5 to 25 mg25\,\text{mg} daily, or eplerenone) to provide distal tubule aldosterone blockade, followed by the sequential addition of β\beta-blockers, centrally acting α2\alpha_2-agonists, or direct vasodilators (hydralazine or minoxidil, which require concomitant β\beta-blockers and loop diuretics to suppress reflex tachycardia and severe sodium retention).

Hypertensive crises are defined by severe elevations in arterial pressure, typically exceeding 180 mm Hg180\,\text{mm Hg} systolic or 120 mm Hg120\,\text{mm Hg} diastolic. A hypertensive emergency is characterized by severe blood pressure elevation accompanied by acute, progressive target-organ damage (hypertensive encephalopathy, intracranial hemorrhage, acute ischemic stroke, acute aortic dissection, acute myocardial infarction, acute pulmonary edema with left ventricular failure, acute renal failure, microangiopathic hemolytic anemia, or eclampsia). Immediate admission to an intensive care unit and parenteral antihypertensive titration is mandatory. The general therapeutic goal is to reduce mean arterial pressure (MAP\text{MAP}) by no more than 25%25\% within the first hour; if stable, SBP\text{SBP} is lowered to 160 mm Hg160\,\text{mm Hg} and DBP\text{DBP} to 100100 to 110 mm Hg110\,\text{mm Hg} over the subsequent 22 to 6 hours6\,\text{hours}, with gradual normalization achieved over the following 2424 to 48 hours48\,\text{hours}. Excessive or precipitous blood pressure reduction must be avoided to prevent cerebral, renal, or coronary hypoperfusion caused by shifted vascular autoregulation curves.

Specific compelling clinical conditions dictate distinct blood pressure targets in hypertensive emergency:

  • Acute aortic dissection: Systolic blood pressure must be reduced to less than 120 mm Hg120\,\text{mm Hg} and heart rate below 60 beats/min60\,\text{beats/min} within the first 20 minutes20\,\text{minutes}. Intravenous β\beta-blockers (esmolol, labetalol) must be administered prior to vasodilators (nitroprusside, nicardipine) to suppress reflex tachycardia and reduce aortic wall shear stress (dP/dtdP/dt).

  • Severe preeclampsia or eclampsia, or pheochromocytoma crisis: Systolic blood pressure should be rapidly lowered to less than 140 mm Hg140\,\text{mm Hg} within the first hour of treatment.

  • Acute ischemic stroke: Blood pressure is not lowered acutely unless the patient is a candidate for intravenous thrombolysis (where blood pressure must be reduced to <185/110 mm Hg< 185/110\,\text{mm Hg} prior to fibrinolysis and maintained below 180/105 mm Hg180/105\,\text{mm Hg} for 24 hours24\,\text{hours}) or presents with extreme hypertension (SBP>220 mm Hg\text{SBP} > 220\,\text{mm Hg} or DBP>120 mm Hg\text{DBP} > 120\,\text{mm Hg}, where an initial 15%15\% reduction over 24 hours24\,\text{hours} is targeted).

  • Acute intracranial hemorrhage: In patients presenting with an SBP\text{SBP} between 150150 and 220 mm Hg220\,\text{mm Hg}, acute reduction of SBP\text{SBP} to less than 140 mm Hg140\,\text{mm Hg} within the first hours provides no clinical benefit and can worsen cerebral perfusion; continuous intravenous infusions (nicardipine, clevidipine, labetalol) should be utilized to control SBP\text{SBP} smoothly while avoiding agents that increase intracranial pressure (hydralazine, nitroprusside, nitroglycerin).

Intravenous pharmacologic agents used in hypertensive emergencies include:

  • Nicardipine: A dihydropyridine calcium channel blocker administered at 5 mg/hour5\,\text{mg/hour}, titrated by 2.5 mg/hour2.5\,\text{mg/hour} every 55 to 15 minutes15\,\text{minutes} to a maximum of 15 mg/hour15\,\text{mg/hour}. It provides predictable arterial vasodilation without affecting cardiac conduction, making it a first-line option across diverse presentations, but is contraindicated in severe aortic stenosis.

  • Clevidipine: An ultrashort-acting dihydropyridine calcium channel blocker formulated in a lipid emulsion, metabolized by vascular and blood esterases with an elimination half-life of 11 to 2 minutes2\,\text{minutes}. Initiated at 11 to 2 mg/hour2\,\text{mg/hour}, the dose is doubled every 90 seconds90\,\text{seconds} until approaching goal, then titrated up to 32 mg/hour32\,\text{mg/hour}. It is contraindicated in patients with severe egg or soybean allergies, advanced aortic stenosis, or severe hyperlipidemia.

  • Labetalol: A combined α1\alpha_1- and nonselective β\beta-adrenergic antagonist (1:71:7 ratio of α\alpha to β\beta blockade when given parenterally) administered as intermittent intravenous boluses of 20 mg20\,\text{mg} over 2 minutes2\,\text{minutes}, followed by 4040 to 80 mg80\,\text{mg} every 10 minutes10\,\text{minutes} (maximum 300 mg300\,\text{mg}), or a continuous infusion of 0.50.5 to 2.0 mg/min2.0\,\text{mg/min}. It decreases blood pressure without causing reflex tachycardia, making it a primary choice in acute aortic dissection, ischemic stroke, and preeclampsia/eclampsia, but is contraindicated in reactive airway disease, severe sinus bradycardia, high-degree heart block, and decompensated heart failure.

  • Esmolol: An ultrashort-acting, cardioselective β1\beta_1-adrenergic antagonist with an elimination half-life of 9 minutes9\,\text{minutes}, administered as an intravenous loading dose of 500\,\text{\mu g/kg} over 1 minute1\,\text{minute} followed by a continuous infusion of 50\,\text{\mu g/kg/min}, titrated up to 200200 to 300\,\text{\mu g/kg/min}. It is preferred for acute aortic dissection when rapid titratability is required.

  • Fenoldopam: A selective dopamine D1D_1 receptor partial agonist that induces systemic and renal arteriolar vasodilation while promoting natriuresis, dosed at 0.10.1 to 0.3\,\text{\mu g/kg/min} and titrated up to 1.6\,\text{\mu g/kg/min}. It maintains renal perfusion in acute renal insufficiency, but is contraindicated in glaucoma due to increased intraocular pressure.

  • Phentolamine: A competitive nonselective α1\alpha_1- and α2\alpha_2-adrenergic antagonist dosed at 11 to 5 mg5\,\text{mg} intravenous bolus, indicated for hyperadrenergic crises (pheochromocytoma resection, monoamine oxidase inhibitor-tyramine reactions, cocaine toxicity, clonidine withdrawal). Unopposed β\beta-blockade must be avoided in these settings.

  • Hydralazine: An intravenous direct arteriolar vasodilator (55 to 20 mg20\,\text{mg} every 44 to 6 hours6\,\text{hours}) with an unpredictable onset (1010 to 30 minutes30\,\text{minutes}) and prolonged duration (22 to 4 hours4\,\text{hours}), limiting its utility as a first-line agent except in preeclampsia.

  • Enalaprilat: An intravenous ACE\text{ACE} inhibitor (0.6250.625 to 1.25 mg1.25\,\text{mg} over 5 minutes5\,\text{minutes} every 6 hours6\,\text{hours}, up to 5 mg5\,\text{mg}), whose blood pressure response depends on circulating renin levels, making it unpredictable in acute crisis; it is contraindicated in acute myocardial infarction, pregnancy, and bilateral renal artery stenosis.

Hypertensive urgency is defined as severe blood pressure elevation (>180/120 mm Hg> 180/120\,\text{mm Hg}) in a stable patient without acute or progressing target-organ damage. Hypertensive urgency does not warrant emergency department referral, acute parenteral medication, or hospital admission. Blood pressure should be lowered gradually over 2424 to 48 hours48\,\text{hours} using oral regimens: re-initiating or increasing doses of home medications, or adding a complementary oral agent (such as a thiazide diuretic or calcium channel blocker). Immediate blood pressure lowering in hypertensive urgency provides no proven clinical benefit and can precipitate ischemic vascular events; clinical outpatient re-evaluation is recommended within 22 to 7 days7\,\text{days}.

Dyslipidemia: Primary and Secondary Prevention

Therapeutic management of dyslipidemia centers on reducing atherosclerotic cardiovascular disease (ASCVD\text{ASCVD}) risk through lifestyle intervention, risk stratification, and evidence-based lipid-lowering pharmacotherapies. The 2018 AHA/ACC\text{AHA/ACC} cholesterol guidelines and the 2022 ACC\text{ACC} Expert Consensus Decision Pathway establish four primary patient management groups:

  1. Clinical ASCVD\text{ASCVD} (Secondary Prevention): Individuals with acute coronary syndrome within the past 12 months12\,\text{months}, prior myocardial infarction, stable or unstable angina, coronary revascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin.

  2. Severe Hypercholesterolemia: Adults aged 2020 to 75 years75\,\text{years} with baseline low-density lipoprotein cholesterol (LDL-C\text{LDL-C}) of 190 mg/dL190\,\text{mg/dL} or greater.

  3. Diabetes Mellitus: Adults aged 4040 to 75 years75\,\text{years} with diabetes and LDL-C\text{LDL-C} between 7070 and 189 mg/dL189\,\text{mg/dL}.

  4. Primary Prevention: Adults aged 4040 to 75 years75\,\text{years} without diabetes or clinical ASCVD\text{ASCVD}, with LDL-C\text{LDL-C} between 7070 and 189 mg/dL189\,\text{mg/dL}, stratified by estimated 10-year ASCVD\text{ASCVD} risk calculated using the Pooled Cohort Equations (PCE\text{PCE}).

Primary prevention risk stratification via the PCE\text{PCE} assesses sex, age, race, total cholesterol, high-density lipoprotein cholesterol (HDL-C\text{HDL-C}), systolic blood pressure, current treatment for hypertension, diabetes status, and smoking status, defining four categories: Low Risk (<5%< 5\% 10-year risk; managed with lifestyle alone); Borderline Risk (5%5\% to 7.4%7.4\%; lifestyle modifications, with moderate-intensity statins considered if risk-enhancing factors are present); Intermediate Risk (7.5%7.5\% to 19.9%19.9\%; moderate-intensity statin targeting an LDL-C\text{LDL-C} reduction of 30%30\% to 49%49\%); and High Risk (≥20%\ge 20\%; high-intensity statin targeting an LDL-C\text{LDL-C} reduction of ≥50%\ge 50\%). Risk-enhancing factors include: family history of premature ASCVD\text{ASCVD} (first-degree male relative aged <55 years< 55\,\text{years} or female relative aged <65 years< 65\,\text{years}); primary hypercholesterolemia (LDL-C\text{LDL-C} 160160 to 189 mg/dL189\,\text{mg/dL}); metabolic syndrome; chronic kidney disease (eGFR\text{eGFR} 1515 to 59 mL/min/1.73 m259\,\text{mL/min/1.73}\,\text{m}^2); chronic inflammatory conditions (psoriasis, rheumatoid arthritis, lupus, HIV/AIDS); history of premature menopause (age <40 years< 40\,\text{years}) or preeclampsia; high-risk ethnicity (e.g., South Asian ancestry); persistent hypertriglyceridemia (≥175 mg/dL\ge 175\,\text{mg/dL}); and elevated circulating biomarkers (high-sensitivity C-reactive protein [hs-CRP\text{hs-CRP}] ≥2.0 mg/L\ge 2.0\,\text{mg/L}, lipoprotein(a) ≥50 mg/dL\ge 50\,\text{mg/dL}, or apolipoprotein B ≥130 mg/dL\ge 130\,\text{mg/dL}). In intermediate-risk or select borderline-risk patients where the statin decision remains uncertain, measuring the coronary artery calcium (CAC\text{CAC}) score provides risk refinement: a score of 00 allows re-evaluation in 5 years5\,\text{years} without a statin (unless diabetes, active smoking, or family history of premature ASCVD\text{ASCVD} is present); a score of 11 to 9999 favors statin initiation, particularly in individuals aged 55 years55\,\text{years} or older; and a score of 100100 or greater, or at/above the 75th percentile for age and sex, establishes a clear indication for statin initiation.

Statins (HMG-CoA reductase inhibitors) competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. Intracellular cholesterol depletion up-regulates cell-surface LDL receptor expression, promoting the clearance of circulating atherogenic apoB-containing lipoproteins. Statins reduce LDL-C\text{LDL-C} by 24%24\% to 60%60\%, decrease triglycerides by 7%7\% to 30%30\%, raise HDL-C\text{HDL-C} by 5%5\% to 15%15\%, and stabilize coronary atheroma. High-intensity statins lower LDL-C\text{LDL-C} by 50%50\% or greater: atorvastatin 4040 to 80 mg80\,\text{mg} daily and rosuvastatin 2020 to 40 mg40\,\text{mg} daily. Moderate-intensity statins reduce LDL-C\text{LDL-C} by 30%30\% to 49%49\%: atorvastatin 1010 to 20 mg20\,\text{mg}, rosuvastatin 55 to 10 mg10\,\text{mg}, simvastatin 2020 to 40 mg40\,\text{mg}, pravastatin 4040 to 80 mg80\,\text{mg}, lovastatin 4040 to 80 mg80\,\text{mg}, fluvastatin 40 mg40\,\text{mg} twice daily or 80 mg80\,\text{mg} extended-release daily, and pitavastatin 11 to 4 mg4\,\text{mg} daily. Low-intensity statins reduce LDL-C\text{LDL-C} by less than 30%30\%: simvastatin 10 mg10\,\text{mg}, pravastatin 1010 to 20 mg20\,\text{mg}, and lovastatin 20 mg20\,\text{mg} daily.

Statin pharmacokinetics differ in lipophilicity, clearance pathways, and drug-interaction profiles. Atorvastatin, lovastatin, and simvastatin are lipophilic molecules cleared primarily by CYP3A4, predisposing them to significant drug interactions with potent CYP3A4 inhibitors (azole antifungals, clarithromycin, erythromycin, protease inhibitors, cobicistat, dronedarone, and grapefruit juice exceeding 1 quart/day1\,\text{quart/day}); simvastatin is restricted to 20 mg/day20\,\text{mg/day} with amiodarone, amlodipine, or ranolazine, and 10 mg/day10\,\text{mg/day} with diltiazem, verapamil, or dronedarone. Fluvastatin, pitavastatin, and rosuvastatin are metabolized via CYP2C9; rosuvastatin is hydrophilic, exhibits an elimination half-life of 19 hours19\,\text{hours}, and must not exceed 10 mg/day10\,\text{mg/day} in severe renal impairment (CrCl<30 mL/min\text{CrCl} < 30\,\text{mL/min}) or 5 mg/day5\,\text{mg/day} with cyclosporine. Pravastatin is hydrophilic, cleared via sulfation without major cytochrome P450 involvement, and carries low drug-interaction risk. Co-administration of gemfibrozil with any statin (particularly simvastatin) is contraindicated due to inhibition of statin glucuronidation, which increases plasma exposure and risk of severe rhabdomyolysis; fenofibrate is preferred when combining fibrates with statins. In 2021, the FDA requested the removal of the absolute contraindication against statin use during pregnancy, though statins should still be discontinued in most pregnant and breastfeeding individuals.

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1\text{NPC1L1}) transporter in the brush border of the jejunal enterocyte, blocking dietary and biliary cholesterol absorption to provide an incremental 18%18\% to 20%20\% reduction in LDL-C\text{LDL-C}. In the IMPROVE-IT trial, adding ezetimibe to simvastatin in post-ACS patients demonstrated a significant reduction in cardiovascular events, establishing ezetimibe as the preferred initial nonstatin adjuvant (Class I in very high-risk clinical ASCVD\text{ASCVD} with LDL-C≥70 mg/dL\text{LDL-C} \ge 70\,\text{mg/dL}; Class IIa in severe hypercholesterolemia with LDL-C≥100 mg/dL\text{LDL-C} \ge 100\,\text{mg/dL} on maximally tolerated statins).

PCSK9 monoclonal antibodies (evolocumab and alirocumab) bind circulating proprotein convertase subtilisin/kexin type 9, preventing the targeted lysosomal degradation of hepatic LDL receptors and accelerating LDL-C\text{LDL-C} clearance. When added to statins, they produce an incremental 45%45\% to 68%68\% reduction in LDL-C\text{LDL-C} and reduce cardiovascular death, myocardial infarction, and stroke (FOURIER, ODYSSEY OUTCOMES). Evolocumab is dosed subcutaneously at 140 mg140\,\text{mg} every 2 weeks2\,\text{weeks} or 420 mg420\,\text{mg} once monthly; alirocumab is dosed subcutaneously at 7575 to 150 mg150\,\text{mg} every 2 weeks2\,\text{weeks} or 300 mg300\,\text{mg} every 4 weeks4\,\text{weeks}. Inclisiran is a small interfering RNA (siRNA\text{siRNA}) conjugated to triantennary N-acetylgalactosamine (GalNAc\text{GalNAc}) that targets hepatocyte asialoglycoprotein receptors to degrade intracellular PCSK9 messenger RNA, lowering LDL-C\text{LDL-C} by approximately 51%51\%. Inclisiran is administered subcutaneously as a 284 mg284\,\text{mg} injection at months 0 and 3, and every 6 months6\,\text{months} thereafter. Cardiovascular outcomes trials for inclisiran are ongoing.

Bempedoic acid inhibits adenosine triphosphate-citrate lyase (ACL\text{ACL}), an upstream enzyme in the hepatic cholesterol synthesis cascade preceding HMG-CoA reductase. Because the activating enzyme (very long-chain acyl-CoA synthetase 1) is present in the liver but absent in skeletal muscle, bempedoic acid lowers LDL-C\text{LDL-C} by 15%15\% to 25%25\% without causing muscle toxicity. In the CLEAR Outcomes trial of statin-intolerant patients, bempedoic acid significantly reduced MACE\text{MACE}. Bempedoic acid inhibits renal tubular organic anion transporter 2 (OAT2\text{OAT2}), leading to hyperuricemia (2%2\% to 3%3\%) and an increased incidence of acute gout; it is also associated with a modest increase in tendon rupture, leukopenia, and elevated transaminases. Co-administration increases concentrations of simvastatin (limit to 20 mg/day20\,\text{mg/day}) and pravastatin (limit to 40 mg/day40\,\text{mg/day}).

Hypertriglyceridemia is categorized as moderate (TG\text{TG} 175175 to 499 mg/dL499\,\text{mg/dL}) or severe (TG≥500 mg/dL\text{TG} \ge 500\,\text{mg/dL}, particularly ≥1000 mg/dL\ge 1000\,\text{mg/dL}). Severe hypertriglyceridemia warrants immediate dietary fat restriction and pharmacotherapy to prevent acute pancreatitis. Secondary causes of hypertriglyceridemia must be evaluated: medications (anabolic steroids, atypical antipsychotics, β\beta-blockers, bile acid sequestrants, oral estrogens, glucocorticoids, protease inhibitors, raloxifene, oral retinoids, sirolimus, thiazide diuretics); dietary factors (excessive alcohol consumption, high-glycemic-index refined carbohydrates, extreme low-fat/high-carbohydrate diets, weight gain); and systemic diseases (uncontrolled diabetes, hypothyroidism, nephrotic syndrome, chronic kidney disease, lipodystrophies). In moderate hypertriglyceridemia, statin therapy is optimized to address cardiovascular risk; if triglycerides remain between 150150 and 499 mg/dL499\,\text{mg/dL} in patients with established ASCVD\text{ASCVD} or diabetes with two or more additional risk factors, prescription icosapent ethyl (2 g2\,\text{g} twice daily with meals) reduces MACE\text{MACE} by 25%25\% (REDUCE-IT). In severe hypertriglyceridemia (TG≥500 mg/dL\text{TG} \ge 500\,\text{mg/dL}), fibrates (fenofibrate 4848 to 145 mg145\,\text{mg} daily, or fenofibric acid) represent first-line therapy to lower triglycerides by 20%20\% to 50%50\% via peroxisome proliferator-activated receptor-alpha (PPAR−α\text{PPAR}-\alpha) activation; gemfibrozil must not be combined with statins.

Clinical Case Studies and Practice Scenarios

Scenario 1: Optimizing GDMT in HFrEF with Active Volume Congestion

A 48-year-old woman (L.S.\text{L.S.}, body weight 69 kg69\,\text{kg}) with alcohol-induced cardiomyopathy presents for follow-up. Her most recent echocardiogram reveals an LVEF\text{LVEF} of 20%20\%, and her functional status is consistent with NYHA\text{NYHA} Class III heart failure. Her current home medications include lisinopril 40 mg40\,\text{mg} daily, furosemide 40 mg40\,\text{mg} twice daily, carvedilol 12.5 mg12.5\,\text{mg} twice daily, spironolactone 25 mg25\,\text{mg} daily, and digoxin 0.125 mg0.125\,\text{mg} daily, which have remained unchanged for the past month. Vital signs include blood pressure 112/70 mm Hg112/70\,\text{mm Hg} and heart rate 72 beats/min72\,\text{beats/min}. Laboratory values demonstrate sodium 140 mEq/L140\,\text{mEq/L}, potassium 4.0 mEq/L4.0\,\text{mEq/L}, chloride 105 mEq/L105\,\text{mEq/L}, bicarbonate 26 mEq/L26\,\text{mEq/L}, blood urea nitrogen 12 mg/dL12\,\text{mg/dL}, serum creatinine 0.8 mg/dL0.8\,\text{mg/dL}, blood glucose 98 mg/dL98\,\text{mg/dL}, calcium 9.0 mg/dL9.0\,\text{mg/dL}, phosphorus 2.8 mg/dL2.8\,\text{mg/dL}, magnesium 2.0 mEq/L2.0\,\text{mEq/L}, and a serum digoxin concentration of 0.7 ng/mL0.7\,\text{ng/mL}. She reports worsening shortness of breath and progressive fatigue over the prior week. Physical examination reveals 2+2+ bilateral lower extremity pitting edema and inspiratory pulmonary crackles.

The most appropriate strategy to maximize the management of her heart failure is to add empagliflozin 10 mg10\,\text{mg} orally daily. SGLT2 inhibitors provide reductions in cardiovascular mortality and heart failure hospitalizations in symptomatic HFrEF\text{HFrEF} irrespective of diabetes status. Increasing carvedilol to 25 mg25\,\text{mg} twice daily is contraindicated during active fluid overload, as initiating or escalating β\beta-blockers in decompensated, hypervolemic patients precipitates acute clinical worsening; β\beta-blocker uptitration should be deferred until complete euvolemia is restored. Lisinopril is already at its maximum recommended heart failure dose (40 mg/day40\,\text{mg/day}), and exceeding this threshold offers no incremental clinical benefit while increasing nephrotoxicity and hyperkalemia. Digoxin is at a therapeutic concentration (0.7 ng/mL0.7\,\text{ng/mL}, within the target range of 0.50.5 to 0.9 ng/mL0.9\,\text{ng/mL}); increasing the dose to 0.25 mg/day0.25\,\text{mg/day} would raise serum concentrations above 1.0 ng/mL1.0\,\text{ng/mL}, conferring an increased risk of proarrhythmia and all-cause mortality without improving efficacy.

Scenario 2: Medication Optimization in Stable Stage C HFrEF with CKD

A 62-year-old man (J.T.\text{J.T.}, height 182.88 cm182.88\,\text{cm}, weight 85 kg85\,\text{kg}) with a medical history of chronic coronary disease (myocardial infarction 3 years ago), hypertension, major depressive disorder, Stage 3 chronic kidney disease (baseline serum creatinine 2.8 mg/dL2.8\,\text{mg/dL}), peripheral arterial disease, osteoarthritis, and hypothyroidism presents for routine evaluation of stable NYHA\text{NYHA} Class II heart failure (LVEF\text{LVEF} 25%25\%). Current medications include aspirin 81 mg81\,\text{mg} daily, atorvastatin 40 mg40\,\text{mg} every night, enalapril 5 mg5\,\text{mg} twice daily, metoprolol succinate 50 mg50\,\text{mg} daily, furosemide 80 mg80\,\text{mg} twice daily, cilostazol 100 mg100\,\text{mg} twice daily, acetaminophen 650 mg650\,\text{mg} four times daily, sertraline 100 mg100\,\text{mg} daily, and levothyroxine 0.1 mg0.1\,\text{mg} daily. Vital signs are blood pressure 128/74 mm Hg128/74\,\text{mm Hg} and heart rate 72 beats/min72\,\text{beats/min}. Laboratory values demonstrate potassium 4.1 mEq/L4.1\,\text{mEq/L}, serum creatinine 2.8 mg/dL2.8\,\text{mg/dL}, and thyroid-stimulating hormone (TSH\text{TSH}) 2.6 mIU/L2.6\,\text{mIU/L}.

The optimal next step to improve his heart failure outcomes is to transition from enalapril to sacubitril/valsartan 24/26 mg24/26\,\text{mg} orally twice daily. Guidelines recommend replacing an ACE\text{ACE} inhibitor or ARB\text{ARB} with an ARNI\text{ARNI} in chronic symptomatic HFrEF\text{HFrEF} to decrease morbidity and mortality. A mandatory 36 hour36\,\text{hour} washout period between the last dose of enalapril and the first dose of sacubitril/valsartan must be observed. The lower starting dose (24/26 mg24/26\,\text{mg} twice daily) is indicated because the patient was taking a low dose of enalapril (5 mg5\,\text{mg} twice daily) and has severe chronic kidney disease. Substituting carvedilol for metoprolol succinate is not indicated, as both are evidence-based β\beta-blockers with equivalent efficacy in clinical trials. Adding spironolactone is contraindicated because his baseline serum creatinine (2.8 mg/dL2.8\,\text{mg/dL}) exceeds the safe threshold (>2.5 mg/dL> 2.5\,\text{mg/dL} in men, or eGFR<30 mL/min/1.73 m2\text{eGFR} < 30\,\text{mL/min/1.73}\,\text{m}^2), placing him at risk for life-threatening hyperkalemia. Adding digoxin is inappropriate because the patient is clinically stable, and his impaired renal function (SCr\text{SCr} 2.8 mg/dL2.8\,\text{mg/dL}) would lead to digitalis accumulation and toxicity.

Scenario 3: Identification of Harmful Medications in Systolic Heart Failure

Regarding the medications taken by the patient in Scenario 2 (J.T.\text{J.T.}), cilostazol should be discontinued immediately. Cilostazol is a phosphodiesterase type 3 inhibitor indicated for intermittent claudication in peripheral arterial disease; however, all phosphodiesterase type 3 inhibitors carry a boxed warning contraindicating their use in patients with heart failure of any severity due to increased ventricular arrhythmias and mortality. Acetaminophen is the analgesic of choice for mild to moderate musculoskeletal pain in heart failure because it avoids the fluid retention, hypertension, and renal impairment associated with NSAIDs\text{NSAIDs}. Sertraline is safe and carries no contraindication in heart failure. Levothyroxine is therapeutic (supported by a normal TSH\text{TSH} of 2.6 mIU/L2.6\,\text{mIU/L}); maintaining euthyroid status is essential because untreated hypothyroidism impairs cardiac contractility and masks symptoms, whereas hyperthyroidism exacerbates systolic dysfunction.

Scenario 4: Anticoagulation Decision-Making in New-Onset Atrial Fibrillation

A 52-year-old man (P.M.\text{P.M.}, height 177.8 cm177.8\,\text{cm}, weight 116 kg116\,\text{kg}) with a history of hypertension and a transient ischemic attack 2 years ago presents with an intermittent "fluttering" chest sensation over several weeks. He takes metoprolol tartrate 50 mg50\,\text{mg} twice daily and aspirin 81 mg81\,\text{mg} daily. He resides 3 hours from his primary care clinic. Vital signs are blood pressure 130/78 mm Hg130/78\,\text{mm Hg} and heart rate 76 beats/min76\,\text{beats/min}. Laboratory values are normal. An electrocardiogram reveals an irregularly irregular rhythm devoid of P waves with a ventricular response of 74 beats/min74\,\text{beats/min}, confirming atrial fibrillation.

The most appropriate management strategy is to initiate oral anticoagulation with dabigatran 150 mg150\,\text{mg} orally twice daily. His ventricular rate is well controlled (74 beats/min74\,\text{beats/min}) on his current β\beta-blocker; adding another AV\text{AV} nodal blocking agent (digoxin or diltiazem) is unnecessary and increases the risk of high-grade atrioventricular block. Evaluating stroke risk yields a CHA2DS2-VASc\text{CHA}_2\text{DS}_2\text{-VASc} score of 3 (hypertension = 1 point; prior TIA\text{TIA} = 2 points), establishing a Class I indication for chronic oral anticoagulation. Direct-acting oral anticoagulants (DOACs\text{DOACs}) are preferred over warfarin. Dabigatran 150 mg150\,\text{mg} twice daily is appropriate because he has intact renal function, demonstrated adherence to a twice-daily regimen, prescription insurance, and an inability to travel for frequent INR\text{INR} monitoring.

Scenario 5: Managing Recurrent Atrial Fibrillation in Decompensated HFrEF

A 67-year-old man (H.D.\text{H.D.}) with a 4-year history of hypertension and atrial fibrillation presents following emergency evaluation for worsening exertional fatigue, palpitations, and lower extremity edema. His medications include ramipril 5 mg5\,\text{mg} twice daily, sotalol 120 mg120\,\text{mg} twice daily, digoxin 0.125 mg0.125\,\text{mg} daily, and warfarin 5 mg5\,\text{mg} daily. Physical examination reveals worsening lower extremity pitting edema and blood pressure 115/70 mm Hg115/70\,\text{mm Hg}, heart rate 88 beats/min88\,\text{beats/min}, and INR\text{INR} 2.82.8. Telemetry displays atrial fibrillation, and an echocardiogram demonstrates a newly reduced LVEF\text{LVEF} of 35%35\% to 40%40\%. The physician elects to maintain a rhythm control strategy.

The most appropriate treatment modification is to discontinue sotalol and initiate amiodarone, loading with 400 mg400\,\text{mg} twice daily and tapering toward a maintenance dose of 200 mg200\,\text{mg} daily. Sotalol is contraindicated in left ventricular systolic dysfunction (LVEF<40%\text{LVEF} < 40\%) and heart failure due to its negative inotropic properties and risk of torsades de pointes. Dronedarone is contraindicated in symptomatic heart failure with recent decompensation due to doubled mortality. Amiodarone and dofetilide are the only two antiarrhythmic agents demonstrated to be safe for rhythm control in HFrEF\text{HFrEF}. When initiating amiodarone, drug interactions must be addressed: the maintenance dose of warfarin must be reduced by 33%33\% to 50%50\% with close INR\text{INR} monitoring, and the digoxin dose must be reduced by 50%50\%.

Scenario 6: Antihypertensive Regimen Design in Post-MI Hypertension

A 55-year-old woman (W.D.\text{W.D.}) recently hospitalized for an acute myocardial infarction treated with a drug-eluting coronary stent presents for follow-up. Her past medical history includes hypertension and gastroesophageal reflux disease. Current medications are clopidogrel 75 mg75\,\text{mg} daily, aspirin 81 mg81\,\text{mg} daily, and atorvastatin 40 mg40\,\text{mg} daily. Vital signs are blood pressure 152/86 mm Hg152/86\,\text{mm Hg} and heart rate 82 beats/min82\,\text{beats/min}. Laboratory values are within normal limits (sodium 140 mEq/L140\,\text{mEq/L}, potassium 4.3 mEq/L4.3\,\text{mEq/L}, serum creatinine 1.0 mg/dL1.0\,\text{mg/dL}).

The most appropriate regimen to treat her hypertension is to initiate dual therapy with lisinopril and metoprolol succinate. Her blood pressure (152/86 mm Hg152/86\,\text{mm Hg}) represents Stage 2 hypertension (≥140/90 mm Hg\ge 140/90\,\text{mm Hg}), exceeding her target (<130/80 mm Hg< 130/80\,\text{mm Hg}) by more than 20/10 mm Hg20/10\,\text{mm Hg}, which warrants prompt initiation of two first-line agents of different classes. In patients with ischemic heart disease and prior myocardial infarction, guidelines specifically recommend combining an evidence-based β\beta-blocker with an ACE\text{ACE} inhibitor (or ARB\text{ARB}) to attenuate neurohormonal activation, reduce myocardial oxygen demand, promote coronary remodeling, and lower recurrent ischemic events and mortality.

Scenario 7: First-Line Antihypertensive Selection in a Black Patient with Elevated ASCVD Risk

A 58-year-old African American woman (T.J.\text{T.J.}) presents for follow-up of chronic obstructive pulmonary disease. Her blood pressure across two standardized visits averages 138/88 mm Hg138/88\,\text{mm Hg}, with a heart rate of 77 beats/min77\,\text{beats/min}. Current medications include daily tiotropium dry powder inhaler and an albuterol inhaler as needed. Laboratory values are normal (SCr\text{SCr} 0.8 mg/dL0.8\,\text{mg/dL}, potassium 4.0 mEq/L4.0\,\text{mEq/L}). Her calculated 10-year ASCVD\text{ASCVD} risk is 12%12\%.

The most appropriate management is to initiate lifestyle modifications and add amlodipine 5 mg5\,\text{mg} once daily. Her average blood pressure (138/88 mm Hg138/88\,\text{mm Hg}) represents Stage 1 hypertension. Because her 10-year ASCVD\text{ASCVD} risk is 10%10\% or greater, the pharmacotherapy threshold is 130/80 mm Hg130/80\,\text{mm Hg}, and lifestyle modifications alone are insufficient. Single-agent pharmacotherapy is indicated because her blood pressure is not 20/10 mm Hg20/10\,\text{mm Hg} above target. In Black adults without heart failure or chronic kidney disease with albuminuria, initial antihypertensive therapy should comprise a dihydropyridine calcium channel blocker (amlodipine) or a thiazide-like diuretic, as these classes achieve greater blood pressure reductions and cerebrovascular event reductions compared to ACE\text{ACE} inhibitors or ARBs\text{ARBs}.

Scenario 8: Statin Selection in Diabetes Mellitus with Multiple ASCVD Risk Factors

A 63-year-old woman (M.M.\text{M.M.}) presents after 6 months of dietary and exercise modifications for dyslipidemia. Her medical history includes hypertension, type 2 diabetes mellitus, and asthma. She smokes one pack of cigarettes per day and consumes three beers daily. Her family history is significant for maternal myocardial infarction at age 42 years42\,\text{years}. Her medications are an albuterol inhaler, lisinopril, metformin, linagliptin, and calcium carbonate. Vital signs include blood pressure 134/84 mm Hg134/84\,\text{mm Hg} and heart rate 75 beats/min75\,\text{beats/min}. Fasting lipid panel reveals HDL-C\text{HDL-C} 38 mg/dL38\,\text{mg/dL}, LDL-C\text{LDL-C} 134 mg/dL134\,\text{mg/dL}, triglycerides 186 mg/dL186\,\text{mg/dL}, and total cholesterol 209 mg/dL209\,\text{mg/dL}; hemoglobin A1C\text{A1C} is 8.6%8.6\%. Her estimated 10-year ASCVD\text{ASCVD} risk is 27.8%27.8\%.

The next step in therapy is to initiate a high-intensity statin (atorvastatin 4040 to 80 mg80\,\text{mg} or rosuvastatin 2020 to 40 mg40\,\text{mg} daily). In patients aged 4040 to 75 years75\,\text{years} with diabetes mellitus, moderate-intensity statin therapy is the baseline recommendation; however, when multiple high-risk ASCVD\text{ASCVD} factors are present (active cigarette smoking, hypertension, low HDL-C\text{HDL-C}, family history of premature ASCVD\text{ASCVD}, 10-year risk ≥20%\ge 20\%), high-intensity statin therapy targeting an LDL-C\text{LDL-C} reduction of 50%50\% or greater is indicated. Initial combination therapy with ezetimibe is not recommended prior to assessing the response to maximally tolerated high-intensity statin monotherapy at a 44 to 12 week12\,\text{week} follow-up.

Scenario 9: High-Intensity Statin Dosing Verification

According to ACC/AHA\text{ACC/AHA} cholesterol guidelines, high-intensity statin therapy is defined as a daily dose that lowers baseline LDL-C\text{LDL-C} by 50%50\% or greater. Atorvastatin 40 mg40\,\text{mg} daily meets this definition (producing an average LDL-C\text{LDL-C} reduction of approximately 50%50\% to 55%55\%). Pravastatin 20 mg20\,\text{mg} and lovastatin 20 mg20\,\text{mg} are low-intensity regimens (lowering LDL-C\text{LDL-C} by <30%< 30\%), whereas rosuvastatin 10 mg10\,\text{mg} daily is classified as moderate-intensity therapy (30%30\% to 49%49\% LDL-C\text{LDL-C} reduction).

Scenario 10: Differentiating Secondary Etiologies of Hypertriglyceridemia

When evaluating a patient with severe dyslipidemia, secondary causes of elevated triglycerides include immunosuppressive agents such as sirolimus. Sirolimus inhibits mammalian target of rapamycin (mTOR\text{mTOR}), impairing lipoprotein lipase activity and up-regulating hepatic very-low-density lipoprotein production, frequently causing severe hypertriglyceridemia. Other pharmacologic causes include anabolic steroids, atypical antipsychotics, β\beta-blockers, bile acid sequestrants, systemic glucocorticoids, oral estrogens, and protease inhibitors. Saturated dietary fats, amiodarone, and extrahepatic biliary obstruction predominantly increase LDL-C\text{LDL-C}, not triglycerides.

Scenario 11: Duration of Dual Antiplatelet Therapy Following DES for ACS

A 66-year-old man presents 14 months following an acute coronary syndrome treated with a drug-eluting coronary stent. His medications include aspirin 81 mg/day81\,\text{mg/day}, prasugrel 10 mg/day10\,\text{mg/day}, sublingual nitroglycerin as needed, metoprolol succinate 75 mg/day75\,\text{mg/day}, ramipril 10 mg/day10\,\text{mg/day}, and atorvastatin 20 mg/day20\,\text{mg/day}. He inquires about the required duration of prasugrel therapy.

The most appropriate instruction is to advise him to consult his physician regarding discontinuing prasugrel at this time. Standard guidelines recommend a minimum duration of 12 months12\,\text{months} of DAPT\text{DAPT} following PCI\text{PCI} for ACS\text{ACS}. Beyond 12 months12\,\text{months}, continued DAPT\text{DAPT} is warranted only in select patients with high ischemic risk and low bleeding vulnerability. Because this patient has achieved 14 months14\,\text{months} of uneventful therapy without ongoing ischemic symptoms, transitioning to single antiplatelet therapy with lifelong aspirin 81 mg81\,\text{mg} daily is the standard course.

Scenario 12: Pharmacologic Conversion and Antiarrhythmic Safety in Post-MI Sustained VT

A 68-year-old man with a history of NYHA\text{NYHA} Class III heart failure (LVEF\text{LVEF} 30%30\%), two previous myocardial infarctions, long-standing hypertension, and diabetic nephropathy (SCr\text{SCr} 2.2 mg/dL2.2\,\text{mg/dL}) is admitted following a syncopal episode. Telemetry documents a 45 second45\,\text{second} episode of sustained monomorphic ventricular tachycardia. Vital signs are blood pressure 120/75 mm Hg120/75\,\text{mm Hg} and heart rate 80 beats/min80\,\text{beats/min}.

The most appropriate intravenous antiarrhythmic regimen for acute conversion is amiodarone 150 mg150\,\text{mg} infused over 10 minutes10\,\text{minutes}, followed by 1.0 mg/min1.0\,\text{mg/min} for 6 hours6\,\text{hours}, then 0.5 mg/min0.5\,\text{mg/min} for 18 hours18\,\text{hours}. Class I antiarrhythmics, including procainamide, are contraindicated in patients with an LVEF<40%\text{LVEF} < 40\% and ischemic cardiomyopathy due to proarrhythmia and negative inotropy. Sotalol is contraindicated in patients with an LVEF<40%\text{LVEF} < 40\% and carries a risk of torsades de pointes in renal insufficiency (SCr\text{SCr} 2.2 mg/dL2.2\,\text{mg/dL}). Dofetilide is ineffective for acute ventricular tachycardia conversion and is indicated only for atrial fibrillation or flutter. Amiodarone is safe and effective for sustained ventricular tachycardia in the setting of severe left ventricular systolic dysfunction and chronic kidney disease.

Scenario 13: Duration of Extracardiac Toxicity Following Amiodarone Discontinuation

If the patient in Scenario 12 subsequently develops amiodarone-induced thyrotoxicosis leading to recurrent ventricular tachycardia, requiring amiodarone cessation, the anticipated duration of hyperthyroidism is approximately 6 months. Amiodarone has an elimination half-life averaging 5858 to 60 days60\,\text{days} due to extensive sequestration in adipose and parenchymal tissues. Resolving systemic toxicities requires three to five elimination half-lives (approximately 55 to 8 months8\,\text{months}) following complete drug cessation.

Scenario 14: Management of QTc Prolongation Induced by Sotalol

A 64-year-old woman with a history of hypertension and an inferior myocardial infarction 6 months ago develops sustained ventricular tachycardia successfully converted with intravenous lidocaine. Electrophysiologic testing confirms inducible ventricular tachycardia, and she is started on sotalol 80 mg80\,\text{mg} orally twice daily. Two hours following the second dose, an electrocardiogram reveals a QTc\text{QTc} interval of 520 ms520\,\text{ms}.

The most appropriate management is to discontinue sotalol and initiate oral amiodarone (400 mg400\,\text{mg} three times daily loading). A QTc\text{QTc} exceeding 500 ms500\,\text{ms} during sotalol therapy confers an unacceptably high risk of drug-induced torsades de pointes, mandating immediate discontinuation. Dofetilide is also a Class III potassium channel blocker with reverse use-dependence and would carry a comparable risk of excessive QTc\text{QTc} prolongation; furthermore, it is not approved for ventricular arrhythmias. Amiodarone prolongs the action potential duration uniformly with minimal dispersion of ventricular repolarization, conferring a low risk of torsades de pointes (<1%< 1\%) and serving as a safe alternative in structural heart disease.

Scenario 15: Treatment Selection in Acute Hypertensive Emergency with Pulmonary Edema

A 68-year-old man with end-stage renal disease on maintenance hemodialysis, chronic coronary disease, HFrEF\text{HFrEF}, and recent cocaine use presents with acute dyspnea, diaphoresis, severe chest tightness, blood pressure 250/120 mm Hg250/120\,\text{mm Hg}, heart rate 122 beats/min122\,\text{beats/min}, bilateral pulmonary crackles, and ST-segment depression in inferior leads. He has missed dialysis and gained 2 kg2\,\text{kg}.

The most appropriate intervention is continuous intravenous nitroglycerin (5\,\text{\mu g/min}, titrated to achieve a maximum 25%25\% reduction in MAP\text{MAP} over the first hour). The patient is presenting with a hypertensive emergency complicated by acute pulmonary edema and acute myocardial ischemia. Nitroglycerin provides rapid venodilation to decrease preload, lower pulmonary capillary wedge pressure, relieve pulmonary congestion, and dilate epicardial coronary arteries without compromising renal clearance. Sodium nitroprusside is contraindicated due to anuria, which prevents the renal clearance of thiocyanate, resulting in rapid thiocyanate toxicity. Labetalol and other β\beta-blockers are contraindicated in acute decompensated heart failure with pulmonary edema; furthermore, lowering MAP\text{MAP} by 50%50\% is overly precipitous and risks cerebral and coronary hypoperfusion. Oral clonidine cannot be titrated predictably in hypertensive emergencies and provides no role in acute pulmonary edema.

Scenario 16: Hypertensive Urgency Secondary to Medication Nonadherence

A 56-year-old woman with chronic hypertension and nonischemic heart failure (LVEF\text{LVEF} 35%35\%) presents to the emergency department with a blood pressure of 210/120 mm Hg210/120\,\text{mm Hg} and a heart rate of 105 beats/min105\,\text{beats/min}. She reports running out of her chronic medications (hydrochlorothiazide, carvedilol, and lisinopril) 3 days ago. She feels mildly lightheaded but exhibits no chest pain, shortness of breath, visual changes, or focal neurologic deficits. Laboratory evaluations and electrocardiography are normal.

The most appropriate strategy is to resume her home oral antihypertensive regimen and arrange outpatient clinical follow-up within 2 days2\,\text{days}. In hypertensive urgency (severe blood pressure elevation in the absence of acute target-organ damage), intravenous antihypertensives and emergency hospitalization are not indicated and are associated with adverse outcomes. The patient's elevation is secondary to abrupt cessation of maintenance therapies; restarting her outpatient regimen restores blood pressure control safely over 2424 to 48 hours48\,\text{hours}. Adding an immediate fourth agent is unnecessary until adherence to her baseline three-drug regimen has been re-established.